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ABSTRACT
 Background: The survival for children born with congenital heart disease (CHD) has in-
creased and the majority reach adult age. Having a cardiac problem raise questions on 
the probability of successful pregnancies and predictors associated with unfavorable out-
come. Heart biomarkers are used in emergency care to evaluate patients with chest symp-
toms. However, normal levels during pregnancy have not been established.
Aims: The aims of the thesis were to study risk of cardiac, obstetric and neonatal outcome 
of pregnancy in women with CHD, and evaluate two risk-classi cations. To obtain addi-
tional diagnostic tools when evaluating pregnant women with chest symptoms. 
Methods: The participants in Paper I and II were single CHD-center cohorts of 232 and 
307 women respectively, with 496 and 580 pregnancies respectively. The women were 
classi ed according to two prevalent risk classi cations (CARPREG and mWHO). In 
Paper I we evaluated maternal age and the applicability of risk classi cations on cardiac, 
obstetric and neonatal outcomes of pregnancy. Paper II addressed parity as a covariate for 
cardiac events. In Paper III national registries, National Patient Register, Medical Birth 
Register and Cause of Death register were used. Women with CHD born 1953-1997 with 
 rst singleton birth 1973-2015 were compared with matched controls without a diagnosis 
of CHD. Outcomes were cardiac, obstetric and neonatal complications. In Paper IV 196 
pre-pregnancy healthy women were recruited from antenatal maternal outpatient clin-
ics. Blood samples were analyzed for heart biomarkers N-terminal pro Brain Natriuretic 
Peptide (NTproBNP) and high sensitive cardiac Troponin T (hs-cTNT) on four occasions 
during and after pregnancy. 
Results: In Paper I in 496 CHD pregnancies, there were 14% cardiac complications, 14% 
obstetric and 15% neonatal complications, comparable with previous single- and multi-
center publications. Severe complications were rare. Age above 35 years was not associ-
ated with worse outcome. The two risk classi cations had moderate diagnostic accuracy 
of 0.71 and 0.65 respectively. In Paper II we analyzed the effect of parity in 307 CHD 
women. We found a high odds ratio of 5.5 (95% CI, 1.8-16.9) to have the same cardiac 
outcome of a second pregnancy as the  rst, if the risk classi cation remained the same. 
In Paper III both cardiac, obstetric and neonatal adverse events were more common in 
6´131 CHD women than in 158´343 controls, but with low absolute numbers. Severe 
complications were very rare. Maternal all-cause mortality during pregnancy and one year 
postpartum was 3/10´000. Perinatal death was 55/10´000 to be compared with 38/10´000 
in controls. During the observation time-period the number and complexity of CHD diag-
noses increased, as did age at  rst birth and maternal weight. In Paper IV we established 
the 95th percentile levels of NTproBNP and hs-cTNT for pre-pregnancy healthy women 
to be below the cut-off levels for the suspicion of heart failure and myocardial ischemia. 
Existing cut-off levels can be used also in pregnant women in the emergency room.
Conclusion: Two established risk classi cations had moderate diagnostic accuracy. The 
maternal outcome of a second pregnancy can be expected to be the same as of the  rst, if 
in stable cardiac situation. The absolute risks for adverse outcome of pregnancy in women 
with CHD are low, but higher than in controls. Existing cut-off levels of heart biomarkers 
can be used also during pregnancy, in pre-pregnancy healthy women.
Keywords: congenital heart disease, pregnancy, risk classi cation, parity, heart bio- 
marker.
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SAMMANFATTNING PÅ SVENSKA
Graviditet hos kvinnor med medfött hjärtfel
 Bakgrund: 
Barn som föds med hjärtfel överlever i betydligt högre utsträckning numera till vuxen 
ålder. Unga kvinnor med medfött hjärtfel (CHD, congenital heart disease) som funde-
rar över graviditet har många frågor om eventuella komplikationer, både för egen del 
och för ett framtida barns del. Två hjärtmarkörer (NTproBNP och hs-cTNT) används 
vid akut andnöd eller bröstsmärta för att utesluta hjärtsvikt eller hjärtmuskelskada, 
men normalvärden för hjärtfriska gravida kvinnor har inte funnits.
Syfte: 
Att studera hjärtrelaterade (kardiella), graviditetsrelaterade (obstetriska) och foster-
relaterade (neonatala) utfall i samband med graviditet hos kvinnor med CHD, samt 
utvärdera två risk-klassi kationer. Att förbättra rådgivning till unga kvinnor med 
medfött hjärtfel inför en eventuell graviditet. Att fastslå normalvärden hos hjärtfriska 
gravida kvinnor för hjärtmarkörer.
Metod: 
I delarbete I och II studerade vi hur det går vid graviditet hos kvinnor med medfött 
hjärtfel  som följs på GUCH/ACHD-centrum, Göteborg. Vi analyserade andel kardi-
ella, obstetriska och neonatala komplikationer utifrån ålder och paritet (antal gravidi-
teter). Vi utvärderade också två tidigare föreslagna risk-klassi kationer. I delarbete III 
använde vi Socialstyrelsens nationella register med avidenti erade löpnummer och 
samkörde Patientregistret, Medicinska födelseregistret (MFR) och Dödsorsaksregist-
ret. Utfall var kardiella, obstetriska och neonatala komplikationer hos förstföderskor 
med singelgraviditet som fanns i MFR 1973-2015, där vi jämförde kvinnor med med-
fött hjärtfel med en kontrollpopulation från samma tidsperiod. Delarbete IV var en 
analys av hjärtmarkörer (NTproBNP och hs-cTNT) hos hjärtfriska gravida kvinnor. 
Blodprov för hjärtmarkörerna togs vid två tillfällen under graviditet, efter förlossning 
samt 6 mån efter graviditeten. 
Resultat: 
Vi analyserade utfallet av 496 CHD-graviditeter och fann 14% kardiella, 14% obstet-
riska och 15% neonatala komplikationer vilket är jämförbart med andra center (del-
arbete I). Det var få allvarliga komplikationer. Ålder över 35 år ökade inte risken för 
komplikationer. De två risk-klassi kationerna var användbara till en måttlig grad. I 
delarbete II fann vi hög sannolikhet (odds ratio 5.5 (95% CI, 1.8-16.9) för att en andra 
graviditet skulle ha samma risk för hjärtkomplikation som den första, under förutsätt-
ning att CHD-kvinnans hjärtsituation var oförändrad. I registren i delarbete III fanns 
6´131 förstföderskor med CHD-diagnos som jämfördes med 158´343 kontroller utan 
CHD-diagnos. Kardiella, obstetriska och neonatala komplikationer var vanligare hos 
CHD-kvinnor jämfört med kontroller, men i absoluta tal var det låga risker och all-
varliga komplikationer var mycket ovanliga. Mödradödlighet (av alla orsaker) under 
6
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graviditet och ett års uppföljning var 3/10´000 hos CHD-kvinnor. Barnadödligheten 
(t o m 6 dagar efter födseln) var 55/10´000 hos CHD att jämföra med 38/10´000 hos 
kontroller. Antalet CHD-kvinnor och svårighetsgraden av CHD ökade under tidspe-
rioden, så också förstföderskornas ålder och vikt. I delarbete IV beskrev vi normala 
nivåer för hjärtmarkörerna hos kvinnor under och efter graviditet. Dessa nivåer var 
under de gränsvärden man använder i övriga befolkningen vid misstänkt hjärtsvikt 
och hjärtmuskelskada och man kan därför använda samma gränsvärden hos gravida 
kvinnor som hos övriga befolkningen.
Slutsats: 
De två risk-klassi kationerna har ett begränsat värde. Det är sannolikt att en andra 
graviditet är förenad med samma risk för hjärtkomplikation som vid den första, om 
mammans hjärtsituation är oförändrad. Det är låg risk för allvarliga komplikationer 
i samband med graviditet hos kvinnor med CHD, men högre jämfört med kontroller. 
De gränsvärden som  nns för hjärtmarkörer (NTproBNP och hs-cTNT) är användbara 
även hos gravida, tidigare hjärtfriska, kvinnor.  
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ACHD  Adult congenital heart disease
APGAR Appearance, pulse, grimace, activity, respiration
ART  Assisted reproductive technology
ASD  Atrial septal defect
AUC  Area under the curve
BMI  Body Mass Index
CHD  Congenital heart disease
CI  Con dence interval
CS  Cesarean section
eGFR  Estimated glomerular  ltration rate
ESC  European society of cardiology
EVF  Erythrocyte volume fraction
GUCH   Grown up congenital heart disease
gw  Gestational weeks
Hs-cTNT High-sensitive cardiac TroponinT
ICD  International classi cation of diseases
IQR  Inter-quartile range
IVF  In-vitro fertilization 
LBW  Low birth weight
MBR  Medical birth register
NPR  National patient register
NTproBNP N-Terminal pro Brain Natriuretic Peptide
PFO  Patent foramen ovale
PPH  Postpartum hemorrhage
PTB  Preterm birth
ROC  Receiver operating characteristic
SD  Standard deviation 
SGA  Small for gestational age
SHBG  Sexual hormone binding globulin
TPR  Total population register
WHO  World Health Organisation
Eisenmenger syndrome  Cyanotic heart defect caused by shunt.
Fontan circulation   Operation technique where the caval veins are   
connected to the pulmonary artery.
Tetralogy of Fallot   Congenital heart defect; pulmonary stenosis, 
hypertrophic right ventricle, VSD and overriding 
aorta.
Mustard-operation   Operation technique for transposition of the great 
arteries, where the blood is redirected via atrial 
reconstruction.
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Historical and to-date perspective
Historical perspective on congenital heart disease 
The modern era of congenital heart disease (CHD) surgery started 
in the 1940´s with the Blalock-Taussig shunt to enhance blood 
supply to the pulmonary circulation(1). In 1944 the  rst operation 
of a child with coarctation of the aorta was performed by Pro-
fessor Crafoord in Sweden(2). Since then the number of pediatric 
cardiac operations have increased to approximately 900 per year 
in Sweden divided between two centers; Gothenburg and Lund(3). 
Advances in diagnostics of congenital heart disease, pediatric cardiac surgery and an-
esthesiology, catheter interventions and general health care have resulted in an increase 
of adult patients with CHD who survive into adulthood at a good health(4-7). Nowadays 
the number of persons with CHD is higher among adults than among children due to 
high survival rates(4). We experience the expected concomitant increase in pregnan-
cies among women with CHD(8-10). To separate the adult patients with CHD from the 
pediatric population the term Adult Congenital Heart Disease (ACHD) has been in 
use in American literature, while Grown Up Congenital Heart Disease (GUCH) was 
used in European literature until recently. Since this is a new category of patients to 
adult cardiac care, as well as obstetric care, research is ongoing to evaluate different 
perspectives on the outcome for both mother and child. 
Approximately 1% of the population is born with CHD(4, 11-14). The fetal heart starts 
evolving early and at 6-7 weeks of age the heart is beating and four heart cham-
bers are developed(15). Many of the cardiac defects develop during this time, includ-
ing conotrunchal defects and the structural changes may progress during pregnan-
cy. Abnormal valves affect blood  ow and may lead to restricted development of 
heart chambers or pulmonary circulation(16, 17).  Birth rates of children with CHD may 
change with increasing fetal diagnostics(11). Between 1999 and 2011, the termination 
rate of pregnancies in Sweden for all detected CHD was 2% while between 2012 and 
2016 it increased to 2.9%. For the severe heart defects, (for example hypoplastic left 
heart syndrome) the termination rate increased from 33% to 52% during the same 
time period. One year survival rate for neonates with severe CHD increased during 
the same period from 82% to 86%(14). 
To-date congenital heart disease
CHD is a heterogeneous group of more than four hundred different diagnoses and 
more than thousand combinations. Figure 1 shows the distribution of diagnoses in 
the Swedish register of congenital heart disease, SWEDCON(3). The most common 
heart defects are septal defects (yellow), which cause shunts between the atrias or 
between the ventricles. The four heart valves can be atretic or stenotic which might 
affect the development of the ventricles. There may be a re-arrangement of atrias, 
ventricles, arterial or venous vessels. Sometimes several defects are combined. The 
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diversity in lesions imply a diversity in survival rate, type of complications, interven-
tions and comorbidities. Some patients are operated at a young age, with different 
operation techniques and outcome, while some CHD diagnoses with less symptoms 
are diagnosed at an adult age. There is a slight predominance of male neonates in the 
incidence of the total CHD cohort, but for some diagnoses (i.e. atrial septal defect) 
there is a female predominance. Survival rates for CHD have increased the last de-
cades and we are still in the beginning of understanding about the impact of acquired 
cardiovascular disease on patients with congenital heart disease(18). There is also an 
increasing interest in the association between obstetric events, e.g. preeclampsia, and 
the risk of future acquired cardiovascular disease in the normal population(19). Since 
survival has increased for women with CHD the long-term effects of obstetric com-
plications, the impact of pregnancy on future CHD prognosis and morbidity will be 
important to study. 
Specialized outpatient clinics for patients with CHD started in the late 1990´s, entitled 
GUCH or ACHD clinics since the existing adult cardiology care units merely cared 
for acquired coronary disease or heart failure in the older population. The GUCH/
ACHD center in Gothenburg, Sweden was initiated in 1996 and is one of two tertiary 
centers in Sweden with cardiac interventions and specialized thoracic surgeons. We 
have close collaboration with the obstetric ward with regular multidisciplinary confer-
ences on the management of pregnancy and delivery since 2008. CHD-cardiologists, 
anesthesiologists and dedicated obstetricians take part in the conferences, together 
with midwives, arrhythmia specialists and other concerned disciplines. The primary 
catchment area is Gothenburg with surroundings (approximately 1.5 million inhabit-
Figure 1. Distribution of CHD diagoses in the SWEDCON register. 
Published with courtesy of SWEDCON.                                                                                            
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ants) and we have referrals from Western and Northern Sweden (altogether approxi-
mately 4.5 millions).
Historical and to-date obstetric care in Sweden 
Sweden, together with Norway and the Netherlands had already in the beginning of 
the 20th century low maternal mortality compared to other countries and it continued 
to decline during the century. In 1904 the maternal mortality rate in Sweden was 
230/100´000 births which in 2015 had declined to 4/100´000(20-22). The reason is prob-
ably multifactorial, but advances in medical, obstetric and antiseptic care and the edu-
cation of community spread midwives may be partial explanations. Perinatal death 
rates have been stable around 3.7/1´000 live births for the last decade, while it was 
7/1´000 in 1973(23). Approximately 100´000 children are born every year in Sweden. 
The Swedish Medical Birth Register (MBR), hosted by the Swedish National Board 
of Health and Welfare (“Socialstyrelsen”) started in 1973 and continuously receive 
information from antenatal clinics, delivery wards and pediatric examination of the 
newborn. From these reports, we have data on, for example, the rate of cesarean sec-
tion (CS) of 5.3% in 1973 that increased to 17.3% in 2018(24-25). In Western countries 
the maternal age at  rst birth has increased and comorbidities are more common in 
primiparous ( rst birth) women compared to some decades ago(10, 26-27). In Sweden, 
age at  rst birth has increased from 24.6 years in 1978 to 28.8 years in 2018. Body 
Mass Index (BMI) at  rst antenatal visit has increased from 23.0 in 1992 to 24.7 in 
2018 and the proportion of obese women with BMI ≥30 has increased during the 
same time from 6% to 15.4%. On the other hand, smoking at  rst antenatal visit has 
decreased from 31.4% in 1983 to 4.2% in 2018(25). The  rst child following assisted 
reproductive technology (ART) in Sweden was born in 1982 and the number of births 
has increased over time. ART includes standard in vitro fertilization, intracytoplasmic 
sperm injection, freezing and thawing of embryos and oocyte and sperm donation. 
Today approximately 5´000 children per year are born after reproductive therapy(25, 28).
Physiology and biomarkers
Normal pregnancy physiology
The  rst signs of cardiovascular changes of pregnancy start early after conception. 
Trophoblasts invade the spiral arteries and affect the endothelium and smooth mus-
cle layers to become a high- ow low-resistance system in the placenta(29).There are 
changes in the uterine artery with increased  ow and lower pulsatility index within a 
few weeks after conception(30-32). The peripheral resistance in the vessels is reduced 
allowing an increase in blood  ow. There is an increased water resorption from the 
kidneys resulting in plasma volume expansion and hemodilution and an increased 
glomerular  ltration(33). There are several humoral changes involved causing these 
changes of the cardiovascular system with adaptive endothelial and vascular function 
and reduced aortic stiffness(34, 35).The changes in the peripheral circulation demand an 
increased cardiac output which is obtained by an increase in both heart rate and stroke 
volume(34, 36-38). The  gure below show that the hemodynamic changes are increasing 
until gestational week (gw) 20-25 when there is a plateau until term when the vas-
cular resistance becomes somewhat increased(36, 39, 40). There are few hemodynamic 
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studies during labor and the early postpartum phase. During delivery cardiac output 
is increased with the uterine contractions, presumably when blood is auto-transfused 
from the uterus(38). Cardiac output remains raised for at least 48 hours after delivery 
despite a fall in heart rate, due to an increase in venous return from the utero-placental 
circulation(41). Within a month postpartum, cardiac output has returned to normal(42). 
Figure 2. Drawing of heart and uterus. Non-pregnant vessels in the uterus to the 
left, and during pregnancy with placenta to the right. Published with permission from 
Sixten Furenäs.
Figure 3. Hemodynamic changes with respect to gestational weeks (A), during labor (B) and 
2 weeks postpartum (C)(40). BP blood pressure, pp postpartum, BC between contractions. 
*For cohorts in (B) and (C), relative changes from baseline were compared with the baseline 
values of the cohort from (A). Published with permission from Oxford University Press.
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Echocardiographic fi ndings in normal pregnancy
The cardiac performance is dependent on preload, afterload, heart rate and contractil-
ity. Left ventricular mass, dimension and left atrial size increase during pregnancy, but 
contractility seem to remain unchanged in several publications. Changes in volumes 
and ventricular mass return to normal within one year postpartum. Some studies also 
found reduced diastolic function at the end of pregnancy, which was reversed within 
one year. Right heart volume is also signi cantly increased both in pregnancy and at 
one-year follow up compared to non-pregnant women(37, 42-44). 
Biochemical changes in normal pregnancy 
There are several changes in biochemical test results during pregnancy due to the 
circulatory changes, the increased metabolic demands and hemostatic, humoral and 
immunologic response. The increase in water resorption lower the erythrocyte vol-
ume fraction (EVF) or hematocrit, and subsequently hemoglobin (Hb). When renal 
glomerular  ltration rate increase by 60% during pregnancy it affects the turn-over 
of biomarkers, why the reference levels at the analyzing lab might be misleading(45). 
The use of heart biomarkers 
Several heart biomarkers re ecting ventricular wall stress or cardiac myocyte injury 
have been studied in previous publications on heart failure or ischemic heart disease 
populations(46, 47). The guideline recommendations of cut-off levels to rule out heart 
failure (NTproBNP <300 ng/l) and myocardial infarction (hs-cTNT <14 ng/l) are ac-
cepted among clinicians(48, 49). In heart failure literature, both Brain Natriuretic Peptide 
(BNP) and N-Terminal Brain Natriuretic Peptide (NTproBNP) have been studied(48). 
In Sweden, NTproBNP with longer half-time is more often used than BNP(50-52 ). Nor-
mal levels in blood donors are reported and serve in some studies as reference popula-
tion. The levels of NTproBNP were higher with age and higher for females compared 
to males within the same age groups in a study on 1980 blood donors. Females in age 
group 18-29 years had median level of 37 pg/ml and in age group 60-69 the median 
was 68 pg/ml. Corresponding median levels for males were 20 and 43 respectively(53). 
In the same study, the effect of renal function on NTproBNP levels was studied and 
median level was 38 pg/ml in blood donors with GFR >91 ml/min and 46 pg/ml in 
persons with GFR 60-90 ml/min. The association with impaired renal function has 
been con rmed in primary care studies and heart failure studies(54-56). 
The association between NTproBNP and sex has been studied with focus on hor-
mones. In a Framingham study population, higher NTproBNP was associated with 
female sex, with the highest levels in premenopausal women receiving oral contra-
ceptives. In both sexes, higher NT-proBNP levels were corresponding to lower free 
testosterone and higher sexual hormone binding globulin (SHBG), adjusted for age, 
BMI and cardiovascular risk factors(57). In postmenopausal women higher NTproBNP 
levels were associated with lower androgens and higher SHBG(58, 59). High BMI was 
associated with low natriuretic peptides in a Framingham population(60). The same 
pattern was seen in the ICON study on NTproBNP and BMI(61). There also seem to 
be differences in levels in different ethnicities with lower levels in Afroamericans 
and Chinese persons compared to Europeans(62). Diseases that can cause ventricu-
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lar wall stress except for systolic heart failure, for example hypertension or thyroid 
disease, exhibit elevated levels of NTproBNP(63, 64). Hyperthyroid patients had more 
than doubled levels of NTproBNP compared with euthyroid controls without signi -
cant changes in left ventricular dimensions or systolic function(65). In CHD literature 
NTproBNP levels vary with complexity of congenital heart disease(65). The European 
guidelines on ACHD recommend serial testing of NTproBNP to identify patients at 
risk of cardiovascular events. Levels above 15.2 pmol/l (or 136 ng/l) has been shown 
to have prognostic value on cardiovascular events and mortality after adjustment for 
age, sex, type of congenital diagnosis and ventricular function(66, 67). In a study on 
cyanotic patients, the effect of high hematocrit (or EVF) was discussed as a con-
tributing factor to the 12-fold higher NTproBNP in cyanotic patients compared with 
controls(68). In the same study oxytocin seemed to stimulate release of NTproBNP in 
atrial myocytes.
In modern ischemic heart disease literature troponins (Troponin I, Troponin T, high 
sensitivity cardiac Troponin T (hs-cTNT)) have been studied(47, 49, 69). At Sahlgrenska 
University Hospital, Gothenburg analyzing lab, hs-cTNT is used, mostly in the emer-
gency room setting to rule in or rule out myocardial infarction. Troponins are thought 
to be released in the blood as a result of myocyte necrosis due to ischemia or in am-
mation. Advanced age and impaired renal function are associated with increased levels 
of troponins, while female sex is associated with lower levels(70-72). Other conditions 
(respiratory disease, sepsis among others) may also exhibit elevated troponins(73). Sev-
eral studies have shown increased troponin levels with exercise; spinning, marathon 
and cycling competition. However, there are diverging opinions if the increase dur-
ing exercise is a result of cardiac cell destruction or from release of troponins from 
the cytosolic compartment of myocytes(74). In a CHD cohort, hs-cTNT was higher in 
diagnoses that are more complex, in arrhythmia, and systemic systolic dysfunction(75).
Heart biomarkers during pregnancy 
There are some publications on different biomarkers in healthy pregnant women with 
blood samples taken at selected time-points during pregnancy, labor and/or postpar-
tum(42, 76-79). In a study on 94 pregnant women NTproBNP was highest in the end of 
the  rst, and beginning of the second trimester (median 73 ng/l at 11-15 gw) com-
pared with the third trimester (median 41 ng/l in 33-41 gw) and a different cohort 
of non-pregnant women (38 ng/l)(76). In another publication on 51 pregnant women 
NTproBNP was elevated during the  rst trimester (median 43 ng/l) compared with 
second and third trimester (28 ng/l). Measurements 2-6 days postpartum were the 
highest (median 127 ng/l) and were higher in women delivered with cesarean section 
(not indicated whether acute or elective) than vaginal delivery(42). Similar  ndings of 
postpartum levels were found in a study on 116 women with median levels of 46 ng/l 
in the second trimester, 36 ng/l in the third trimester and 108 ng/l within 2 days post-
partum. At six months postpartum in the same cohort, levels were 41 ng/l(77). Sample 
size and study design, timing of blood samples and choice of controls were different 
in the studies why direct comparison is dif cult. A related natriuretic peptide, BNP, 
has been evaluated in pregnancy studies, but is not used at our lab(80-83). Pregnancy re-
lated complications of preeclampsia or peripartum cardiomyopathy have shown to be 
associated with increased levels of NTproBNP(84). Women with severe preeclampsia 
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had ten times higher median levels of NTproBNP compared with women with ges-
tational hypertension or normal subjects(85). There was a strong positive correlation 
between NTproBNP and creatinine. In pregnant CHD women, NTproBNP above 128 
ng/l at 20 gw predicted cardiovascular events during pregnancy(86).
Cardiac troponins, but not hs-cTNT, have been studied in few publications during 
pregnancy. In a study on 51 healthy women during labor and early peripartum lev-
els of several cardiac markers were studied. They found Troponin I (TNI) to have 
the highest level 24 hours postpartum but still below upper limit of normal for that 
assay (0.134 vs 0.15 ng/mL)(79). When obtaining repeated hs-TNI during pregnancy 
in 51 healthy women third trimester levels were higher than  rst trimester (median 
1.3 vs 0.8). The highest levels were found day 2-6 postpartum (median 2.3 ng/l) and 
higher in women with vaginal delivery compared with cesarean section. There was 
no information on upper limit of normal(42). In a study on 150 women  divided in non-
pregnant, healthy pregnant and hypertensive pregnant women cTNT was not elevated 
in healthy pregnant women at 36 weeks gestation compared to non-pregnant but sig-
ni cantly increased in preeclamptic women(78).
Pregnancy-associated complications in general population
Obstetric complications Frequency 
Miscarriage 15-20/100 (early in pregnancy) 
Hypertensive disorders of pregnancy 2-8/100 
Thromboembolism 13/10´000 
Postpartum hemorrhage 3-7/100 
Gestational diabetes 1-14/100 
Peripartum cardiomyopathy 1/5´700 
Maternal mortality 12/100´000 
Neonatal complications 
Preterm birth 5/100 
Low birth weight/small gestational age 5-6/100 
Perinatal death 4-5/1´000 
Frequencies refer to populations in high income countries, further described in text. 
Table 1. Pregnancy complications in general population
Obstetric complications in general population
Miscarriage and terminations 
Miscarriage occur frequently, even though not always recognized if it occurs early 
in pregnancy. At 4-6 weeks gestational age, the rate of pregnancy loss is 15%-20%. 
The most common cause is chromosomal abnormalities within the fetus. Other causes 
can be infections, thrombophilia, uterine abnormalities or endocrine disorders(87). In 
a Swedish study, 25% of ever-pregnant women reported at least one miscarriage(88). 
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There are some publications on different biomarkers in healthy pregnant women with 
blood samples taken at selected time-points during pregnancy, labor and/or postpar-
tum(42, 76-79). In a study on 94 pregnant women NTproBNP was highest in the end of 
the  rst, and beginning of the second trimester (median 73 ng/l at 11-15 gw) com-
pared with the third trimester (median 41 ng/l in 33-41 gw) and a different cohort 
of non-pregnant women (38 ng/l)(76). In another publication on 51 pregnant women 
NTproBNP was elevated during the  rst trimester (median 43 ng/l) compared with 
second and third trimester (28 ng/l). Measurements 2-6 days postpartum were the 
highest (median 127 ng/l) and were higher in women delivered with cesarean section 
(not indicated whether acute or elective) than vaginal delivery(42). Similar  ndings of 
postpartum levels were found in a study on 116 women with median levels of 46 ng/l 
in the second trimester, 36 ng/l in the third trimester and 108 ng/l within 2 days post-
partum. At six months postpartum in the same cohort, levels were 41 ng/l(77). Sample 
size and study design, timing of blood samples and choice of controls were different 
in the studies why direct comparison is dif cult. A related natriuretic peptide, BNP, 
has been evaluated in pregnancy studies, but is not used at our lab(80-83). Pregnancy re-
lated complications of preeclampsia or peripartum cardiomyopathy have shown to be 
associated with increased levels of NTproBNP(84). Women with severe preeclampsia 
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had ten times higher median levels of NTproBNP compared with women with ges-
tational hypertension or normal subjects(85). There was a strong positive correlation 
between NTproBNP and creatinine. In pregnant CHD women, NTproBNP above 128 
ng/l at 20 gw predicted cardiovascular events during pregnancy(86).
Cardiac troponins, but not hs-cTNT, have been studied in few publications during 
pregnancy. In a study on 51 healthy women during labor and early peripartum lev-
els of several cardiac markers were studied. They found Troponin I (TNI) to have 
the highest level 24 hours postpartum but still below upper limit of normal for that 
assay (0.134 vs 0.15 ng/mL)(79). When obtaining repeated hs-TNI during pregnancy 
in 51 healthy women third trimester levels were higher than  rst trimester (median 
1.3 vs 0.8). The highest levels were found day 2-6 postpartum (median 2.3 ng/l) and 
higher in women with vaginal delivery compared with cesarean section. There was 
no information on upper limit of normal(42). In a study on 150 women  divided in non-
pregnant, healthy pregnant and hypertensive pregnant women cTNT was not elevated 
in healthy pregnant women at 36 weeks gestation compared to non-pregnant but sig-
ni cantly increased in preeclamptic women(78).
Pregnancy-associated complications in general population
Obstetric complications Frequency 
Miscarriage 15-20/100 (early in pregnancy) 
Hypertensive disorders of pregnancy 2-8/100 
Thromboembolism 13/10´000 
Postpartum hemorrhage 3-7/100 
Gestational diabetes 1-14/100 
Peripartum cardiomyopathy 1/5´700 
Maternal mortality 12/100´000 
Neonatal complications 
Preterm birth 5/100 
Low birth weight/small gestational age 5-6/100 
Perinatal death 4-5/1´000 
Frequencies refer to populations in high income countries, further described in text. 
Table 1. Pregnancy complications in general population
Obstetric complications in general population
Miscarriage and terminations 
Miscarriage occur frequently, even though not always recognized if it occurs early 
in pregnancy. At 4-6 weeks gestational age, the rate of pregnancy loss is 15%-20%. 
The most common cause is chromosomal abnormalities within the fetus. Other causes 
can be infections, thrombophilia, uterine abnormalities or endocrine disorders(87). In 
a Swedish study, 25% of ever-pregnant women reported at least one miscarriage(88). 
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Prenatal screening has increased the termination rate of fetuses with chromosomal de-
fects the last twenty years. The proportion of terminations for severe congenital heart 
defects discovered prenatally has also increased from around 8% to 11% during the 
same time. There are different termination rates for different cardiac diagnoses with 
just over 50% termination rate for hypoplastic left heart syndrome(14). The informa-
tion given to the parents, gestational age, future prognosis, social situation, local law 
among other factors in uence the decision(89). 
Hypertensive disorders of pregnancy
Pregnancy can be complicated by pregnancy-induced hypertension (gestational hy-
pertension) or preeclampsia. Both are de ned as systolic blood pressure ≥140 and/or 
diastolic ≥90 mmHg on more than one occasion, after 20 weeks of gestation. In pre-
eclampsia there is also end-organ involvement with renal proteinuria (≥300 mg/24 h), 
renal insuf ciency, thrombocytopenia, impaired liver function, neurological symp-
toms or fetal growth restriction as manifestations(90-92). Seldom preeclampsia progress 
into eclampsia with seizures, which is a life-threatening condition. Preeclampsia com-
plicates 2-8% of pregnancies in different populations, with 4.8% in a Nordic popu-
lation with a higher incidence (5-10%) in the  rst pregnancy(93, 94). Risk factors for 
preeclampsia is previous preeclampsia, multiple gestation, diabetes mellitus, chronic 
hypertension, obesity, age above 35 years and ART among others(91, 94, 95). The under-
lying cause is not fully understood but seem to involve angiogenic imbalances in the 
maternal-fetal circulation. There is an association between preeclampsia and future 
maternal cardiovascular disease(96). Hypertensive disorders account for 10-25% of 
maternal deaths worldwide; in Sweden it is the most common direct (i.e. no underly-
ing disease) cause of maternal death, accounting for 15% of all maternal mortality in 
Sweden 2007-2017(93, 97). Fetal complications associated with hypertensive disorders 
are preterm birth, intrauterine growth restriction and perinatal mortality.  
Thromboembolism
There is an increase in coagulation factors II, VII, VIII and X during pregnancy that 
promote thrombosis. Together with stagnation of venous return caused by the grow-
ing uterus, there is an increased risk of pulmonary embolism, pelvic thrombosis and 
deep venous thrombosis during pregnancy(98-100). A Swedish register study found an 
incidence of venous thromboembolism of 13/10 000 pregnancies. Half of them were 
within the  rst twelve weeks postpartum. There was an association with cesarean 
section, smoking and preeclampsia(101). Thrombophilia, previous thromboembolism, 
obesity, advanced age, caesarean section and immobilization, multiple gestations are 
some risk factors reported in other publications(102). Pulmonary embolism is one of 
the most common direct cause of maternal mortality in high resource countries and 
the second most common direct cause in Sweden, accounting for 10% of all maternal 
deaths(97, 103).
Postpartum hemorrhage
Postpartum hemorrhage (PPH) is a common cause worldwide to maternal mortality 
but in high resource countries, the mortality rate is low among the 3-7% of all preg-
nancies complicated with PPH. There are different de nitions used for PPH; one of 
them is >500 ml blood loss at vaginal delivery or >1000 ml at cesarean section (which 
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is dif cult to assess). After cesarean section, the blood is mixed with amniotic  uid 
why a higher volume is accepted. Another de nition is 10% lowering of hemato-
crit or erythrocyte volume fraction (EVF, the fraction of red blood cells in the blood 
volume), which will be in uenced by the plasma volume(104, 105). In Sweden PPH is 
de ned as >1000 ml irrespective of delivery mode. The main cause is to be found 
within the obstetric situation with retained placenta, uterine atony, lacerations or in-
strumental delivery associated factors. Risk factors are among others previous PPH, 
coagulopathies, multiple gestation, obesity, and of course anticoagulation medication.
Other maternal complications
Gestational diabetes mellitus complicates 1-14% of pregnancies, depending on the 
studied population, de nition and screening methods. Risk factors are among others 
obesity, familial diabetes, advanced maternal age and previous gestational diabetes. 
Since the risk factors tend to remain the recurrence rate in the next pregnancy is 
high(106, 107). Other endocrine complications as suboptimal thyroid function may oc-
cur(108).
Cardiac complications during pregnancy are not common in the general population. 
Peripartum cardiomyopathy, when heart failure develops at late pregnancy or within 
the  rst months postpartum without previously known heart disease, is associated 
with preeclampsia. Since the incidence is varying in the world, genetic factors might 
play a role(109). In Sweden, the incidence was one per 5 719 deliveries in 1997-2010(110). 
Spontaneous dissection of coronary vessels is an unusual cause of myocardial infarc-
tion in the population, but do occur in pregnant women(111). Aortic dissection in wom-
en without genetic syndromes is unusual, but was the most common indirect cause of 
death in a Swedish national cause-of-death register study(20). Atherosclerotic ischemic 
heart disease has increased coinciding with increased maternal age and BMI. Ischemic 
heart disease is associated with increased maternal mortality(103, 112). In a systematic 
review 32% of women with pre-existing ischemic heart disease had cardiovascular 
complications during pregnancy and congenital anomalies in the offspring was found 
at a higher rate than expected(113).
Maternal mortality
The incidence of maternal mortality, up to one year postpartum, is varying between 
different pats of the world with 216 maternal deaths per 100´000 live births in 2015, 
or 0.2%, which is a 44% decrease since 1990 according to WHO reports(21, 114). Direct 
causes of maternal mortality are de ned as complications associated with the preg-
nancy, while indirect causes are associated with concomitant disease. Hemorrhage is 
the leading cause of maternal death in Africa and Asia, while hypertensive disease 
caused the majority of the maternal deaths in Latin America. In high income coun-
tries, the maternal mortality was 12 per 100´000 live births in 2015, corresponding to 
a lifetime risk of maternal mortality of 1 in 4900 in high income countries compared 
to 1 in 36 in sub-Saharan Africa. In the Nordic countries maternal mortality in the 
general population was 7.2/100 000 live births 2005-2013(115). In UK/Irish, Nordic and 
Swedish reports cardiovascular disease is the main indirect cause of maternal mortal-
ity(97, 103, 115). Figure 4 shows cause of maternal deaths (n=168) in the Nordic countries 
2005-2013. The major cause of cardiovascular deaths in the Nordic countries was 
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aortic dissection (10 out of 28). In the latest UK/Irish report 2009-2014 the majority 
of cardiac deaths were sudden arrhythmic deaths (47 out of 153) and ischemic heart 
disease (34 out of 153). CHD accounted for 3 out of 28 of cardiac deaths in the Nordic 
report and 11 out of 153 in the UK/Irish report. The majority of cardiac deaths oc-
curred 1-42 days postpartum.
Figure 4. Cause of maternal deaths (n=168) in the Nordic countries 2005-2013(115).
Published with permission from John Wiley and Sons.
Delivery mode 
Delivery mode is affected by tradition and cultural aspects as well as the health care 
services provided in different countries. In a WHO world enquiry in 2012 54 countries 
had cesarean section (CS) rates of <10%, and 46 countries have  gures of >20%. In 
Sweden the CS rate was 17%, in Canada 26%, in the USA 30% and in the Netherlands 
13%(116). Negative consequences of CS are intraoperative injury, hemorrhage, infec-
tion and thromboembolism as well as complications associated with an upcoming 
pregnancy. In a comparison between vaginal delivery and CS without medical indi-
cation the OR for hemorrhage was 2.5 (95% CI, 2.1-3.0) and for infection 2.6 (95% 
CI, 1.8-3.8) for women delivered with CS. There were also increased risks for the 
infants, for instance respiratory problems(117). Statistics from Swedish National Board 
of Health and Welfare report around 17% CS in Sweden from 2006 to 2018. In recent 
years the proportion of planned CS has increased compared with acute CS (9.6% vs 
7.6%)(25).
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Fetal/neonatal complications in general population
Preterm birth 
Preterm birth (PTB) is de ned as delivery before 37 gw (or <259 days) from the  rst 
day of the woman’s last menstruation. Very preterm birth is de ned as delivery before 
32 gestational weeks(118). There are two main categories of PTB: medically indicated 
PTB or spontaneous PTB. Medically indicated are PTB caused by maternal or fetal 
complications (decision by obstetrician, sometimes called iatrogenic PTB). Spontane-
ous PTB can start with either spontaneous preterm pre-labor rupture of the membranes 
or spontaneous preterm labor with intact membranes. Spontaneous PTB comprises 
60-75% of all PTBs and 25% to 40% are indicated(119, 120). Risk factors for spontaneous 
PTB are previous preterm birth, maternal disease, and pregnancy characteristics (e.g. 
multiple birth, infections or smoking)(121, 122). In Sweden the rate of PTB before 37 gw 
was 5.4% in 2018(25). In a population-based study 1991-2001 on preterm births, 55.2% 
were spontaneous and 20.2% were indicated (75% vs 25% when excluding intrauter-
ine fetal death, congenital malformations and unknown onset). The authors found an 
association with PTB and smoking, primiparity, and advanced maternal age(119). PTB 
account for 75% of perinatal mortality and have a risk of long-term morbidity with 
neurodevelopmental, gastrointestinal or respiratory problems(120, 123). 
Low Birth Weight/Small for Gestational Age 
Low Birth Weight (LBW) is de ned as birth weight ≤2500g and very low birth weight 
is de ned as birth weight ≤1500g. There are several de nitions on Small for Gesta-
tional Age (SGA) based on estimation of gestational age, birthweight and sex and 
is a statistical measurement. One de nition is a birthweight more than two standard 
deviations below the gestational age and sex speci c reference curve(124, 125). Intrauter-
ine growth restriction is another term in literature, which means that the rate of fetal 
growth is less than normal for the growth potential of that speci c infant. There are 
several risk factors for LBW and SGA; sociodemographic, maternal pre-existing dis-
ease, obstetric complications (e.g. hypertensive disorders of pregnancy) and multiple 
pregnancy. The incidence of low birth weight varies in the world and is 5-6% in the 
Scandinavian countries(126, 127). Complications for the fetus include risk of perinatal 
mortality, intellectual/behavioral dif culties, cerebral palsy and metabolic syndrome 
at adult age(128, 129).
Stillbirth/Perinatal death
The de nition of stillbirth is fetal death ≥22+0 gestational weeks (before July 2008 
it was ≥28+0 gestational weeks in Sweden)(130). Perinatal death include stillbirth and 
early neonatal death <7 days. The rates of perinatal death differ worldwide depend-
ing on socioeconomic factors and health care systems. In the year 2000 Sweden 
had less than 5/1000 total births while parts of Africa and Asia had 70-100 perinatal 
deaths/1000 total births in a WHO report(131). In low and middle income countries in-
fections, poor maternal care and hypertensive disease are some causes. In high income 
countries perinatal mortality is associated with preterm birth, maternal medical issues 
including hypertensive disease and smoking(132). Late neonatal death (day 7-27) was 
30/1000 live births in the world in the year 2000 and in western Europe 3/1000 live 
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births(131). The rate of stillbirths in Sweden was 3.7/1000 live births and early neonatal 
death 1.5/1000 in 2015(23).
Pregnancy-associated complications in women with heart disease (con-
genital and acquired)
Cardiac complications during pregnancy in women with heart disease (con-
genital and acquired)
In the literature on pregnancy and heart disease, the cohorts often consist of both con-
genital and acquired heart disease. Acquired heart disease include for example rheu-
matic valvular disease, ischemic coronary disease and arrhythmia without structural 
abnormalities. When possible, the CHD proportion of the cohorts were identi ed in 
the studies and speci ed below.  
Heart failure
Heart failure, when there is insuf cient cardiac output to support oxygenation of the 
tissues, is reported to occur in 1.6% to 13.1% of pregnancies in women with heart 
disease(133, 134). Heart failure is de ned in different reports as either symptoms signi -
cant for heart failure, hospitalization, echocardiographic/radiologic  ndings and/or an 
International Classi cation of Diseases (ICD) code of heart failure. In women with 
pre-existing heart disease, onset of peripartum cardiomyopathy on top of the heart 
disease is most likely not possible to distinguish from heart failure caused by the un-
derlying heart disease. Heart failure is more common in the third trimester and early 
postpartum than in the  rst and second trimester(135). In studies on maternal congenital 
heart disease exclusively, the rate of heart failure is 1.6-6.2%(133, 136). Cardiac diagnosis 
and morphology, previous cardiac events and comorbidities, socioeconomic factors 
and health care system contribute to outcome. 
Arrhythmia
Arrhythmias are common in pregnancy, even without pre-existing cardiac disease, 
as a consequence of increased plasma volume and hormonal changes(137). Supraven-
tricular tachycardia of short duration is not uncommon in normal population preg-
nancies(138).  Some of the CHD diagnoses have an increased risk of arrhythmias also 
without pregnancy, due to hemodynamic factors or surgical scarring. Arrhythmias in 
the context of heart disease in pregnancy literature is de ned as either electrophysi-
ological registration of tachycardia, hospitalization, initiation of medication against 
tachycardia or clinically strong suspicion of hemodynamically important arrhythmia. 
The incidence of arrhythmia during pregnancy in women with heart disease is re-
ported to be from 0.6% in a low risk population to 9.1% in a Brazilian cohort with a 
majority having acquired heart disease(133, 139-141). Previous episodes of arrhythmia is 
naturally a strong predictor for arrhythmia during pregnancy. Arrhythmias seem to 
be more common in the second and third trimester than early in pregnancy or post-
partum(135, 142, 143). Women with heart disease, especially valvular disease, and atrial 
 brillation or  utter during pregnancy have a higher mortality compared to women 
without atrial arrhythmia, probably re ecting a more severe heart condition(143, 144). In 
the CHD subgroup of a multinational prospective study arrhythmias were prevalent in 
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2% of the pregnancies to be compared with 0.2-0.7% in two American general popu-
lation obstetric discharge note registers(136, 143-145). A multicenter retrospective study on 
CHD women exclusively reported 4.7% arrhythmias during pregnancy(133).
Thromboembolism
Pregnancy is associated with an increased risk of thromboembolism. In CHD, the 
cyanotic heart defects, such as Eisenmenger syndrome, have an impaired hemostasis 
with increased risk of both thrombosis and hemorrhage(146). Patients with shunts with-
out cyanosis (e.g. simple secundum atrial septum defect, ASD) are not known to have 
an increased risk of thromboembolism per se in the absence of predisposing factors 
as thrombophilia (hereditary, factor V Leiden). On the other hand, if the ASD patient 
is affected by venous thrombosis there is a possibility for paradoxal embolization 
from venous to arterial vessels causing coronary embolus, stroke or other end-organ 
ischemia(147, 148). In the general population, the prevalence of patent foramen ovale 
(PFO) is estimated to 15-25%(149, 150). The presence of PFO allow for paradoxal em-
bolization but has no hemodynamic impact and is not considered a congenital heart 
defect, however the ICD-code is the same as for ASD. Thromboembolism during 
pregnancy in women with heart disease is not reported in all publications. When data 
are available, an incidence of 0.6 to 2.8% is reported(141, 151). In the CHD subgroup in a 
large multicenter register, thromboembolism was reported in 1.5% of pregnancies(136). 
Thromboembolism during pregnancy in women with mechanical valve prosthesis is 
a feared complication, why anticoagulation regime need to be addressed(86, 103, 133, 152).
Mortality
Mortality during pregnancy or in the peripartum period in women with heart disease 
has been reported to be 0.4% to 1%  in large cohorts of women with various structural 
heart diseases in a multicenter register(140, 153). In the subgroup of CHD pregnancies 
maternal mortality was reported to 0.2%(136). Depending on study cohort mortality 
has been reported to be as high as 3.6% in a Brazilian study(141). However, mortality 
was not speci ed as cardiac cause in those publications. In a Canadian publication, 
cardiac death was reported in a cohort consisting of 64% women with CHD to be 
0.3% during pregnancy and six months of follow up(135). In selected subgroups such as 
Eisenmenger syndrome the mortality rate is reported to be as high as 8 to 36%(154, 155). 
Structural changes
There are some studies with echocardiographic evaluation during and after pregnan-
cy in CHD patients(156-159). Cornett et al found signs of reduced diastolic function in 
women with structural heart disease during and 6 months after pregnancy compared 
with pre-pregnancy measurements(156). Uebing et al compared CHD-women with and 
without pregnancy and had similar echocardiographic  ndings in both cohorts except 
for women with Tetralogy of Fallot patients. Women with this CHD-diagnosis had 
persisting increase in right ventricle volume after pregnancy(157). Guedes et al fol-
lowed women with Mustard-operated transposition before, during, and more than 2 
years postpartum. They found persisting systemic ventricle dilatation and dysfunc-
tion, however there was no control population(158). In pregnant women with the same 
CHD diagnosis, with non-pregnant women and men as controls Bowater et al found 
increased deterioration of the systemic ventricle in the pregnant women(159). 
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births(131). The rate of stillbirths in Sweden was 3.7/1000 live births and early neonatal 
death 1.5/1000 in 2015(23).
Pregnancy-associated complications in women with heart disease (con-
genital and acquired)
Cardiac complications during pregnancy in women with heart disease (con-
genital and acquired)
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There are few long-term reports on the effect of pregnancy on future complications, 
the need for reoperation or future perspectives. Balint et al found cardiac complica-
tions during pregnancy in CHD women to be associated with cardiac events and in-
terventions within a median follow up of 2.6 years(160). In a questionnaire follow-up 
11 years after last pregnancy two thirds of the 65% who answered the questionnaire 
reported good health, which correlated with physical activity. Ten patients out of 158 
died during the follow up (with a substantial proportion of lost to follow up)(161). There 
is an increasing interest in pregnancy-related complications, such as preeclampsia, 
and risk of future cardiovascular disease in normal population(162-164). The association 
with CHD pregnancy complications and future acquired cardiovascular disease has 
not been studied.
 
Obstetric and neonatal complications in women with heart disease (con-
genital and acquired)
Miscarriage
The rate of miscarriages is dif cult to estimate since the pregnancy may not have been 
reported to health care providers. In a multicenter study patients with heart disease 
were enrolled at the  rst antenatal visit and they reported a miscarriage rate after their 
 rst visit of 3%(151). When using a Dutch/Belgian registry on congenital heart defects 
exclusively with retrieval of medical records the miscarriage rate before gestational 
week 20 was 19.4%(133). In a literature review of 48 retrospective publications on dif-
ferent CHD diagnoses, a total 15% miscarriage rate was reported although varying 
between diagnoses with Fontan circulation and cyanotic heart defects with the highest 
incidence of 40%(165). Oxygen saturation <85% is associated with growth restriction, 
preterm birth and high incidence of perinatal death(166).
Hypertensive disorder of pregnancy
Preeclampsia/eclampsia occur in 2.2-4.7% in different publications on heart disease 
to be compared with 2-5% in Western healthy populations(133, 136, 153, 165, 167). In a Ca-
nadian register study, the incidence of severe preeclampsia was 1.9% in the CHD 
population compared to 1.3% in women without CHD(168). There may be differences 
in the incidence of preeclampsia between different lesions. Some studies include ART 
treated patients while data on other risk factors for preeclampsia not are addressed, 
such as multiple birth(133, 165, 169). Coarctatio aortae (CoA) is a CHD-lesion with an in-
creased risk of pre-existing hypertension. In a multicenter study, 2.6% of pregnancies 
in CoA women were complicated by preeclampsia and the risk was higher if there 
was pre-existing hypertension(170). Similar results, which are in accordance with the 
general population, were found in CoA in a Dutch CHD register cohort(171). A recent 
meta-analysis failed to identify CHD as a risk factor for preeclampsia(172).
Postpartum hemorrhage 
Postpartum hemorrhage is reported to occur in 2.4–11.5% in cohorts of women with 
heart disease with the majority being CHD populations(133, 136, 139, 151, 153). Obstetric health 
care services, delivery mode and medication may affect the incidence. In women with 
mechanical valves, which require anticoagulation, the incidence of postpartum hem-
orrhage is 10%(152). The use of anticoagulants and cyanotic heart disease have been 
shown to be associated with postpartum hemorrhage(151).
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Delivery mode
Delivery mode varies by tradition and health care services in different countries for 
the general population as well as for women with heart disease. In a Canadian study 
of women with heart disease, 27% were delivered by cesarean section (CS) with a 
majority being for obstetric indication (96%). There was no signi cant difference in 
cardiac events in women delivered vaginally (3%) or by CS (4%)(151). Vaginal delivery 
occurred in 65% of the patients and CS in 35% (primarily for obstetric indication) in 
women with heart disease in a report from Brasilia. In <5% of these cases, CS was in-
dicated by heart disease, such as diseases of the aorta, cardiomyopathy, Eisenmenger’s 
syndrome, severe left ventricular obstructive out ow diseases, or pulmonary vascular 
disease(141). There is no consensus in mode of delivery with different cardiac diagno-
ses where one must weigh the negative consequences of CS against the possibility to 
plan for a complicated delivery with adequate personnel and consultants present.  In a 
multicenter study on women with various heart diseases 44% delivered with CS. An 
analysis showed no difference in outcome between planned CS and vaginal delivery 
except for the neonates being more preterm and with lower birth weight in the CS 
group(173) . In Sweden the rate of CS in the general population has been approximately 
17% the last decade(174). The ESC guidelines state that CS for cardiac reason should 
be considered for patients presenting in labor on oral anticoagulants, with aggressive 
aortic pathology, or in acute intractable heart failure. CS is advised in severe forms of 
pulmonary hypertension including Eisenmenger’s syndrome(175).
Assisted reproductive technology 
The use of assisted reproductive technology (ART) has increased the last decades. 
Women with some CHD diagnoses seem to have an increased risk of infertility and 
increased use of ART compared with healthy women(169). The use of ART is associated 
with a higher rate of hypertensive disorders of pregnancy, preterm birth and low birth 
weight mainly due to the higher rate of multiple pregnancy in ART compared with 
spontaneous conception. However, also ART singletons have a higher risk for adverse 
perinatal outcome(176, 177).
Fetal/neonatal outcomes
Preterm birth (12-18%), low birth weight or small for gestational age (3.7-14%) are 
the most common neonatal adverse outcomes(133, 139, 151). The cause of preterm birth is 
multifactorial and a proportion is iatrogenic and indicated by the maternal cardiac, 
obstetric or fetal condition. Kloster et al found an association between PTB, SGA and 
complexity of maternal CHD. Educational level was also associated with these neo-
natal complications, however independent of CHD(178). There is a higher incidence of 
fetal (1-1.3%) and neonatal (0.3-1.2%) deaths in women with acquired and congeni-
tal heart disease compared to healthy women(139, 151). Some multicenter studies report 
a total fetal loss of 1.5-4%(133, 136). The offspring outcomes are highly correlated to 
maternal cardiac complications during pregnancy(133). Women with CHD were more 
often born preterm themselves and gave birth to preterm neonates in a Swedish regis-
ter study(179). The interaction between cardiac performance and utero-placental blood 
 ow has also attracted some interest since the infants of women with CHD more often 
are delivered PTB and SGA(180-182). 
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Familial recurrence of cardiac malformation
Recurrence of CHD is probably multifactorial with genetic, socioeconomic and en-
vironmental contributing factors. There are different reports on the rate of recurrence 
of congenital heart defects in the offspring of women with CHD. There are also au-
tosomal inherited syndromes with CHD as common feature, e.g. Noonans syndrome, 
22q11-deletion syndrome. Multifactorial  recurrence (i.e. no detected gene) were re-
ported to have recurrence rates between 1% to 5.8% in a review, while autosomal 
dominant are inherited in 50%(183). 
Some studies report birth defects as a group, and not speci ed as congenital heart 
defects. A Swedish nationwide register study found an increased risk of any birth 
defects in neonates of CHD women compared to non-CHD (6.7% vs 3.6%)(179). When 
analyzing the recurrence in neonates to men with CHD during the same era in Sweden 
they found no difference between men with or without CHD(184). The data were on all 
birth defects as one group and were registered only at birth. A Canadian register study 
found major visible congenital anomalies in 1.3% vs 0.6% in women with CHD com-
pared to non-matched controls(168). The registration of anomalies in these studies is 
reported from birth discharge notes and some defects may not have been found within 
the perinatal period. 
A Danish report with linking of several nationwide registries including a multi-gener-
ation register found a relative risk of 3.21 (95% CI, 2.96-3.49) for CHD in  rst-degree 
relatives. Depending on type of lesion the recurrence risk was three- to eightyfold 
compared to total population with a CHD prevalence of 103 per 10 000 live births. Of 
the CHD-cases in the population 2.2% were attributed to CHD in a  rst-degree rela-
tive(185). Children with CHD are more often born with intrauterine growth restriction 
according to a recent review(186). The European guidelines on congenital heart disease 
report recurrence rates depending on diagnosis of 2% to 18% for women and 1% to 
4.5% for men(67).
CHD cohort studies and risk classifi cations
CHD cohort studies
There is an increasing amount of literature on women with cardiac disease and preg-
nancy, Table 2. Most of them are retrospective cohort studies and there are a few 
prospective register studies and national registry studies. There are no randomized tri-
als on, for example, delivery mode or medication due to ethical and medical reasons. 
Some publications focus on women with CHD, while others also include women with 
acquired heart disease. In most studies, outcomes are cardiac, obstetric and neonatal 
events, but some focus on maternal cardiac events. 
Considering the hemodynamic changes in normal pregnancy the concern has been 
whether women with low cardiac output from start can increase cardiac output cor-
responding to the demands from the fetus and if the increase in plasma volume would 
cause congestion. Women with out ow valvular stenoses can only increase stroke 
29







 % of total 
cohort



































et al 2013 (153) 











et al 2019 (136) 






















Cardiac complication include heart failure, arrhythmia, and thromboembolic event. Mortality include all cause 
mortality. Obstetric complications include pregnancy-induced hypertension, (pre)eclampsia, and postpartum 
hemorrhage. Neonatal complications include fetal and neonatal mortality, preterm birth, low birth weight. The 
complications are not mutually exclusive.  aNumber of women not reported. bOf whom 1321 were derived from 
previous study . cOf whom 289 (14%) pregnancies were derived from previous study.  dInclude preterm labor 
and HELLP syndrome. eLow birth weight not presented.  fOnly cardiac cause of death reported. N.a. = not 
applicable. 
Table 2. Listed below are a summary of some of the large clinical cohort studies (>100 pregnancies) 
and their outcomes
volume to a certain degree and thereby have a restricted cardiac output even if the 
ventricles are unaffected. Pre-existing arrhythmias can accelerate during pregnancy 
and cause hemodynamic instability. The growing uterus cause venous congestion and 
decreased preload which can cause symptoms in preload dependent circulations such 
as Fontan circulation. 
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Table 3. Risk classifi cations







Prior cardiac event 
















0 p: 5 % 
1 p: 27 % 
 2 p: 75 % 
Neonatal risk:  
Increasing with points,  
no specified percentages. 
ZAHARA 
(133)
Prior arrhythmia  
NYHA functional class III/IV  
Left heart obstruction (peak LVOT gradient >50 mm Hg or aortic valve 
area <1.0 cm2  
Mechanical valve prosthesis  
Systemic atrioventricular valve regurgitation (moderate/severe)  
Pulmonary atrioventricular valve regurgitation (moderate/severe)  
Cardiac medication before pregnancy 1. 
Cyanotic heart disease (corrected and uncorrected)  
Twin or multiple gestation  















 <0.50 p: 2.9 % 
0.51–1.50 p: 7.5%  
1.51–2.50 p: 17.5% 
2.51–3.50 p: 43.1% 
>3.51 p: 70% 
Neonatal risk: 
<0.50 p: 19.9%  
0.50–0.99 p: 33.3% 
1.0–1.49  p: 46.7% 




Prior cardiac event or arrhythmia 
Baseline NYHA III-IV or cyanosis 
Mechanical valve 
Ventricular dysfunction 
High risk left-sided valve disease 
Pulmonary hypertension 
Coronary artery disease 
High risk aortopathy 
No prior cardiac intervention 











 Cardiac risk: 
0-1 p: 5% 
2 p: 10% 
3 p: 15% 
4 p: 22% 





Small or mild pulmonary stenosis, patent ductus arteriosus, mitral valve 
prolapse. 
Successfully repaired simple lesions 
Atrial or ventricular 
ectopic beats. 
Class I  Class I: no detectable  
increased risk of maternal  
mortality and no/mild  
increase in morbidity. 
Cardiac risk: 5-10%  
Unoperated atrial or ventricular septal defect 
Repaired tetralogy of Fallot 
Most arrhythmias 
Turner syndrome without aortic 
dilatation 
Class II  Class II: small increased  
risk of maternal mortality 
or moderate increase 
 in morbidity 
Cardiac risk: 5.7-10.5% 
Mild left ventricular impairment 
Hypertrophic cardiomyopathy 
Native or tissue valve disease 
not considered WHO I or IV  
Mild aortopathy 
Repaired coarctation 
Atrioventricular septal defect 
Class II-III  Class II-III: intermediate 
 increased risk of maternal 
mortality or moderate  
to severe increase  
in morbidity 
Cardiac risk: 10-19% 
Moderate left ventricular 
impairment  
Previous peripartum cardiomyopathy 
without any residual impairment 
Mechanical valve 
Systemic right ventricle mildly decreased 
ventricular function 
Fontan circulation. 
Unrepaired cyanotic heart disease 
Other complex heart disease 
Moderate mitral stenosis 
Severe asymptomatic aortic 
stenosis 
Moderate aortaortopathy  
Ventricular tachycardia 
Class III  Class III: significantly 
 increased risk of  
maternal mortality or severe 
morbidity 
Cardiac risk: 19-27% 
Pulmonary arterial hypertension 
Severe systemic ventricular dysfunction  
Previous peripartum cardiomyopathy 
with residual impairment 
Severe mitral stenosis 
Severe symptomatic aortic stenosis 
Systemic right ventricle 
with moderate or 





Fontan with any complication 
Class IV  Class IV: extremely high 
 risk of maternal mortality 
 or severe morbidity,  
pregnancy is contra-indicated 
Cardiac risk: 40-100% 
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The Siu et al cohort was a Canadian multicenter study including 13 hospitals. The 
authors considered the selection bias to be low. In the CHD proportion of the cohort 
(n=434), 7% had a cardiac event, half of them heart failure and there was one death. 
From the total cohort predictors for adverse events were found, entitled CARPREG I 
score, Table 3.
The cohort from Avila et al was a single center Brazilian cohort with the majority of 
patients having rheumatic valve disease. The complications in the total cohort were 
high with maternal mortality 2.7% and stillbirth 2.9%. In the CHD proportion of the 
cohort (n=191 pregnancies) heart failure was reported in 11.5%, arrhythmia in 2%, 
maternal mortality 3.7%, preterm birth 16% and stillbirth 5.2%. The majority of ma-
ternal mortality were in Eisenmenger patients. In the total cohort of heart disease, 
including rheumatic valve disease, there were 26 pregnancies with mechanical valve 
prosthesis of whom four had thromboembolic events. No speci c predictors were 
evaluated in the study. 
Drenthen et al reported data from the national databases on CHD in the Netherlands 
and Belgium run by seven tertiary centers. It is a retrospective study of medical charts, 
excluding deceased patients why mortality was not reported. There was a selection of 
patients giving informed consent to review the records. Besides the predictors from 
the CARPREG I score the authors found three additional predictors for adverse car-
diac and neonatal events in a multivariate analysis entitled ZAHARA, Table 3. 
Both cohorts from Roos-Hesselink et al are from the ROPAC investigation (Registry 
of Pregnancy and Cardiac Disease), which was initiated by the European Society of 
Cardiology (ESC) Working Group on Grown-Up Congenital Heart Disease and Val-
vular Heart Disease 2007. The register include prospective data from 53 high- and 
low-income countries. There is likely to be a selection bias from centers with more 
frequent cases of heart disease in pregnancy. Mortality was reported up to one week 
postpartum. The participants in the two reports were somewhat different with a higher 
proportion of women from emerging countries and with more severe heart disease in 
the later report. 
Silversides et al reported cardiac events exclusively, from a cohort of women receiv-
ing care at two tertiary care centers, Toronto and Vancouver. The authors separated the 
predictors into general, lesion-speci c and delivery-of-care predictors. In addition to 
previous CARPREG I and ZAHARA predictors, the authors found additional predic-
tors of unfavorable outcome, Table 3. 
In addition to predictors derived from cohort studies, a risk classi cation adapted from 
World Health Organization based on cardiac lesions was proposed(187). It was adopted 
in the ESC guidelines on cardiovascular diseases during pregnancy(175). Lesions were 
classi ed modi ed WHO class I-IV with I judged as low risk and IV recommended 
against pregnancy, Table 3.
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Table 3. Risk classifi cations
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Class I  Class I: no detectable  
increased risk of maternal  
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increase in morbidity. 
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Most arrhythmias 
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Class II  Class II: small increased  
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 in morbidity 
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 increased risk of maternal 
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to severe increase  
in morbidity 
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Fontan circulation. 
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Class III  Class III: significantly 
 increased risk of  
maternal mortality or severe 
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Severe systemic ventricular dysfunction  
Previous peripartum cardiomyopathy 
with residual impairment 
Severe mitral stenosis 
Severe symptomatic aortic stenosis 
Systemic right ventricle 
with moderate or 





Fontan with any complication 
Class IV  Class IV: extremely high 
 risk of maternal mortality 
 or severe morbidity,  
pregnancy is contra-indicated 
Cardiac risk: 40-100% 
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The Siu et al cohort was a Canadian multicenter study including 13 hospitals. The 
authors considered the selection bias to be low. In the CHD proportion of the cohort 
(n=434), 7% had a cardiac event, half of them heart failure and there was one death. 
From the total cohort predictors for adverse events were found, entitled CARPREG I 
score, Table 3.
The cohort from Avila et al was a single center Brazilian cohort with the majority of 
patients having rheumatic valve disease. The complications in the total cohort were 
high with maternal mortality 2.7% and stillbirth 2.9%. In the CHD proportion of the 
cohort (n=191 pregnancies) heart failure was reported in 11.5%, arrhythmia in 2%, 
maternal mortality 3.7%, preterm birth 16% and stillbirth 5.2%. The majority of ma-
ternal mortality were in Eisenmenger patients. In the total cohort of heart disease, 
including rheumatic valve disease, there were 26 pregnancies with mechanical valve 
prosthesis of whom four had thromboembolic events. No speci c predictors were 
evaluated in the study. 
Drenthen et al reported data from the national databases on CHD in the Netherlands 
and Belgium run by seven tertiary centers. It is a retrospective study of medical charts, 
excluding deceased patients why mortality was not reported. There was a selection of 
patients giving informed consent to review the records. Besides the predictors from 
the CARPREG I score the authors found three additional predictors for adverse car-
diac and neonatal events in a multivariate analysis entitled ZAHARA, Table 3. 
Both cohorts from Roos-Hesselink et al are from the ROPAC investigation (Registry 
of Pregnancy and Cardiac Disease), which was initiated by the European Society of 
Cardiology (ESC) Working Group on Grown-Up Congenital Heart Disease and Val-
vular Heart Disease 2007. The register include prospective data from 53 high- and 
low-income countries. There is likely to be a selection bias from centers with more 
frequent cases of heart disease in pregnancy. Mortality was reported up to one week 
postpartum. The participants in the two reports were somewhat different with a higher 
proportion of women from emerging countries and with more severe heart disease in 
the later report. 
Silversides et al reported cardiac events exclusively, from a cohort of women receiv-
ing care at two tertiary care centers, Toronto and Vancouver. The authors separated the 
predictors into general, lesion-speci c and delivery-of-care predictors. In addition to 
previous CARPREG I and ZAHARA predictors, the authors found additional predic-
tors of unfavorable outcome, Table 3. 
In addition to predictors derived from cohort studies, a risk classi cation adapted from 
World Health Organization based on cardiac lesions was proposed(187). It was adopted 
in the ESC guidelines on cardiovascular diseases during pregnancy(175). Lesions were 
classi ed modi ed WHO class I-IV with I judged as low risk and IV recommended 
against pregnancy, Table 3.
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Evaluation of risk classifi cations
The risk classi cations have been evaluated by external datasets(139, 140, 188-192). Depend-
ing on study design, collection and selection of cohorts, risk pro le of cohorts, de ni-
tion of complications and health care systems, among other factors the performance of 
the classi cations differ(193). For the CARPREG I the area under the receiver operating 
characteristic (ROC) curve (AUC) is 0.57-0.73, for the ZAHARA score 0.68-0.74 and 
mWHO 0.65-0.77. The CARPREG II score was recently evaluated in a pilot study of 
100 patients with similar AUC as CARPREG I(194). 
Adding pre-pregnancy signs of heart failure or atrial  brillation and no previous car-
diac intervention was suggested to increase the AUC for mWHO score in the ROPAC 
registry(140). In a meta-analysis shown below (Figure 5) the risk models were consid-
ered to have a moderate discrimination where the mWHO and ZAHARA were found 
to be somewhat better in predicting cardiac complications in women with congenital 
heart disease than CARPREG I(195).  
Figure 5. Meta-analysis of risk classifi cations, Wang et al(195). Pooled area under the 
curve c-statistic for the A) modifi ed World Health Organization (mWHO), B) CARPREG 
I and C) ZAHARA scores. Published with permission from John Wiley and Sons. 
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The study by Balci et al was a prospective multicenter study with a diversity of CHD 
diagnoses, while one third of the patients in the retrospective study by Lu et al had 
surgically corrected shunts(188, 190). The cardiac complication rate was higher in the 
Balci study, which indicate a cohort with more severe CHD. The study by Fu et al was 
on a Chinese CHD cohort consisting of 76% shunt lesions of whom almost half were 
operated(191). The Pijuan cohort were 31% non-CHD(189). The van Hagen cohort was 
from the ROPAC register(140).
Nationwide register studies on CHD and outcomes of pregnancy 
The Danish and Swedish registries are similar with the possibility to link between 
registries based on a unique personal identi cation number. In Sweden reporting to 
registries have been mandatory since 1987 to National In-Patient Register (NPR), to 
National Out-Patient Register since 2001 and since 1973 to the Medical Birth Reg-
istry (MBR). In Denmark, inpatient diagnoses have been reported since 1977 and 
outpatient diagnoses from 1995 onwards. The Danish Medical Birth Register started 
in 1978. Discharge note registries, as in the American and Canadian reports, are not 
linked to personal identi cation number why the registration report number of hospi-
talizations and not number of patients. There is a possibility that the same person is 
registered several times. Further, it is not possible to link between registries and the 
possibility to do long-term follow up is less. The publication from Hayward et al cov-
ers only the state of California. Canada have two registration systems with Quebec 
separated from the rest of Canada. They report discharge notes with the same disad-
vantages as for the American register studies. The maternal and neonatal outcomes are 
reported as composite outcomes in the Canadian study (Table 4).
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The overall aim of the thesis is to enhance pre-pregnancy counseling and care during 
pregnancy in women with congenital heart disease. The different papers correspond 
to frequently asked questions in the clinical situation.
The speci c aims of the four studies in the thesis were
Paper I
To evaluate existing risk classi cations in a single center cohort of pregnant women 
with congenital heart disease. We also studied the effect of maternal age on cardiac, 
obstetric and neonatal outcome in the same cohort. Our hypothesis was that the over-
all complication rate was acceptable, that advanced maternal age could contribute to 
increased risk and that the risk classi cations were useful.
Paper II 
To study the risk of cardiac complications during pregnancy (and two years of follow 
up) based on parity (number of pregnancies >12 gestational weeks) in a single center 
cohort of women with congenital heart disease. Our hypothesis was that women who 
were without cardiac complications during the  rst pregnancy were at low risk during 
a second pregnancy. 
Paper III
To study cardiac, obstetric and neonatal outcome of pregnancy in women with con-
genital heart disease compared with matched controls using several national regis-
tries. Our hypothesis was that complication rates in CHD pregnancies would be lower 
in a nationwide register than in selected cohorts.
Paper IV
To de ne normal levels of heart biomarkers (NTproBNP and hs-cTNT) during preg-
nancy in healthy women (and relate to cut-off levels in non-pregnant women). Our 
hypothesis was that NTproBNP would increase during pregnancy but to a degree 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The overall aim of the thesis is to enhance pre-pregnancy counseling and care during 
pregnancy in women with congenital heart disease. The different papers correspond 
to frequently asked questions in the clinical situation.
The speci c aims of the four studies in the thesis were
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To evaluate existing risk classi cations in a single center cohort of pregnant women 
with congenital heart disease. We also studied the effect of maternal age on cardiac, 
obstetric and neonatal outcome in the same cohort. Our hypothesis was that the over-
all complication rate was acceptable, that advanced maternal age could contribute to 
increased risk and that the risk classi cations were useful.
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To study the risk of cardiac complications during pregnancy (and two years of follow 
up) based on parity (number of pregnancies >12 gestational weeks) in a single center 
cohort of women with congenital heart disease. Our hypothesis was that women who 
were without cardiac complications during the  rst pregnancy were at low risk during 
a second pregnancy. 
Paper III
To study cardiac, obstetric and neonatal outcome of pregnancy in women with con-
genital heart disease compared with matched controls using several national regis-
tries. Our hypothesis was that complication rates in CHD pregnancies would be lower 
in a nationwide register than in selected cohorts.
Paper IV
To de ne normal levels of heart biomarkers (NTproBNP and hs-cTNT) during preg-
nancy in healthy women (and relate to cut-off levels in non-pregnant women). Our 
hypothesis was that NTproBNP would increase during pregnancy but to a degree 




The participants and study design of Paper I-IV included in the 
thesis are summarized below.
 Paper I Paper II Paper III Paper IV 










Population Pregnancies in women 








1997. CHD diagnosis 
in the National Patient 




recruited from four 
maternal antenatal care 
units in the Gothenburg 
area.
Study period 1997-2012 1997-2015 1997-2015 2015-2017 
Data source Medical and obstetric 
records of consecutive 
patients 





Register, Medical Birth 
Register, Cause of 
Death  
















6´131 women with 
CHD, 158´343 
matched controls with 
singleton delivery. 
196 pre-pregnancy 
healthy women. Blood 
tests on four serial time 
points.  
Objective Performance of two 
risk classifications. 
Maternal age as 
covariate. 
Cardiac outcome 
during and after 
pregnancy with parity 
status as covariate. 
Nationwide data on 
maternal, obstetric and 
neonatal complications. 
Estimation of normal 
levels of heart 
biomarkers and their 
variation within the 




CARPREG I and 
mWHO 
CARPREG I and 
mWHO 
 ICD-10 code Q20  26, 
and corresponding 
ICD-7, -8  and -9 
codes. Hierarchal 
categorization in 6 
lesion groups 
No CHD 




pregnancy and two 
years follow up. 
Cardiac, obstetric and 
neonatal outcome 
during pregnancy and 
one-year postpartum. 
95th percentile of heart 
biomarker levels. 
Comparison with 
existing cut-off levels 
for heart failure and 
myocardial infarction.  




class or CARPREG 
score and age into the 
models. 
Longitudinal model 
predicting outcome of 




Descriptive statistics on 
numbers and %. Odds 
ratio with 95% CI 
comparing CHD with 
non-CHD controls. 
Repeated measures 
analysis of variance. 
Point-biserial 
correlation coefficients 
for cut-off values for 
biomarkers. 
Table 5. Summary of the four papers included in the thesis
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Study participants
Paper I and II
The study population consisted of consecutive female patients with adult congenital 
heart disease at the GUCH-center at Sahlgrenska University Hospital/Östra, Gothen-
burg, Sweden who were followed during pregnancy. The majority of patients have 
regular visits, not only during pregnancy, at the center. The women who became preg-
nant were prospectively registered. There are seven GUCH centers in Sweden; two 
of them tertiary centers with Gothenburg being one of the two. The catchment area is 
around 3.5 million inhabitants. We are aware that there are patients with congenital 
heart disease in Sweden that are lost to follow up in adult care and patients with sim-
ple lesions that may give birth at the local hospital without regular visits at a GUCH 
center. Still, we believe that patients from local hospitals with more severe/advanced 
heart disease are referred to us for evaluation and planning of pregnancy and delivery, 
as well as for pre-pregnancy counseling. GUCH Gothenburg have had regular mul-
tidisciplinary pregnancy conferences since 2008 and is located close to and in close 
collaboration with the obstetric clinic at Sahlgrenska University Hospital, which is the 
largest obstetric clinic in Sweden with approximately 10 000  births per year.
Inclusion Paper I. All pregnancies 1997-2012 are included, also terminations and 
miscarriages. Data on pregnancy outcome including previous pregnancies, miscar-
riages and legal terminations were retrospectively collected from medical and ob-
stetric records.  A few patients with operated mitral stenosis were included since we 
did not know the genesis of the mitral valve disease. Both operated and non-operated 
patients were included. Patients with acquired heart disease or non-structural arrhyth-
mia were excluded. 
Inclusion Paper II. Women with pregnancies >12th gestational week 1997-2015 were 
included. The women in Paper I (n=232) are included in the 307 women in Paper II. 
Exclusion criteria were the same as for Paper I, and twin pregnancies. 
Paper III
We used national health data registries held by the Swedish National Board of Health 
and Welfare (Socialstyrelsen) to identify women with a diagnosis of CHD and matched 
them with non-CHD women from the population by age at  rst birth and year of deliv-
ery. Swedish citizens have a unique personal identi cation number, which is changed 
to a de-identi ed code after linkage of registries to avoid identi cation of registries. 
Data linked to that individual can be searched within several different registers. It is 
mandatory for health care providers to report to health data registers. CHD women 
were found in the National Patient Register (NPR) where in-patient diagnoses (from 
1964, full coverage from 1987) and out-patient diagnoses (from 2001) are registered. 
We included women who had reached an age of 15 years and had a registration in the 
Medical Birth Register (MBR, from 1973) for their  rst, singleton delivery. Women 
with a solitary diagnosis of patent ductus arteriosus not present above the age of three 
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stetric records.  A few patients with operated mitral stenosis were included since we 
did not know the genesis of the mitral valve disease. Both operated and non-operated 
patients were included. Patients with acquired heart disease or non-structural arrhyth-
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Inclusion Paper II. Women with pregnancies >12th gestational week 1997-2015 were 
included. The women in Paper I (n=232) are included in the 307 women in Paper II. 
Exclusion criteria were the same as for Paper I, and twin pregnancies. 
Paper III
We used national health data registries held by the Swedish National Board of Health 
and Welfare (Socialstyrelsen) to identify women with a diagnosis of CHD and matched 
them with non-CHD women from the population by age at  rst birth and year of deliv-
ery. Swedish citizens have a unique personal identi cation number, which is changed 
to a de-identi ed code after linkage of registries to avoid identi cation of registries. 
Data linked to that individual can be searched within several different registers. It is 
mandatory for health care providers to report to health data registers. CHD women 
were found in the National Patient Register (NPR) where in-patient diagnoses (from 
1964, full coverage from 1987) and out-patient diagnoses (from 2001) are registered. 
We included women who had reached an age of 15 years and had a registration in the 
Medical Birth Register (MBR, from 1973) for their  rst, singleton delivery. Women 
with a solitary diagnosis of patent ductus arteriosus not present above the age of three 




Participants were recruited from four antenatal outpatient clinics in socioeconomical-
ly mixed areas in Gothenburg. A note in the waiting room at the antenatal outpatient 
clinic informed the pregnant women about the on-going study and if they were inter-
ested in participating, they received oral and written information and signed informed 
consent. 
Participants were 201 healthy women without other medication than supplementa-
tion during pregnancy. Two women withdrew consent. We excluded two women with 
multiple gestation and one with previously unknown congenital heart disease from 
the  nal analysis. The blood samples from the women who had miscarriage were 
included. These women were later contacted and offered physical examination and 
echocardiography outside the study.   
Methods
Paper I and II 
At Sahlgrenska University Hospital there are two electronic medical record systems, 
one for medical and one for obstetric care, available for data collection based on ev-
ery citizen’s individual social security number. Previous cardiac surgery in childhood 
and adulthood, comorbidities, symptoms and signs of cardiac disease were found in 
the medical records. Antenatal data, outcome of previous pregnancies and detailed 
information on mode of delivery, complications and neonatal outcome were found 
in the obstetric records. Data on pregnancy outcome including previous pregnancies, 
miscarriages and legal terminations were retrospectively collected from medical and 
obstetric records. Miscarriage was classi ed as “early” if it occurred before 13 gw. 
Classi cation of women in two risk classi cations (CARPREG I and mWHO) was 
made retrospectively by three experienced GUCH cardiologists and double-checked 
by one of them. We chose not to analyze the more complex ZAHARA classi cation 
since it was found to be inferior to mWHO in a previous publication(188). CARPREG 
II classi cation was not available at the time. 
Paper I. We analyzed number of pregnancies and not women, why women who had 
corrective heart intervention between two pregnancies were calculated as one preg-
nancy with non-operated heart disease and one with operated heart disease. Outcome 
were cardiac, obstetric and neonatal events during consecutive pregnancies. Outcome 
de nitions are reported in Paper I. We analyzed age as a covariate and dichotomized 
to ≤ or >35 years of age, a cut off often used in obstetric reports.
Paper II. We calculated number of women instead of number of pregnancies and 
chose a cut-off of 18 years, where non-operated were considered all women not oper-
ated before the age of 18. Miscarriages later than 12th gestational week were included 
in Paper II since the hemodynamic changes of pregnancy were considered to possibly 
affect maternal cardiac outcome. Outcome was cardiac complications associated with 
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each pregnancy and within two-year follow up. Outcome de nitions are reported in 
Paper II. We analyzed the impact of previous pregnancy outcome on the next preg-
nancy.
Paper III
We used the National Patient register (NPR), Medical Birth register (MBR) to  nd 
cases with CHD and the Total Population Register (TPR) to  nd matched controls. 
Cases were characterized as having International Classi cation of Diseases (ICD)-10 
diagnoses Q 20-Q 26 and corresponding classi cation codes in earlier ICD versions, 
ICD-7, ICD-8 and ICD-9. They were further classi ed into six major lesion groups 
in accordance with previous studies. Controls were matched for sex, age and year of 
 rst birth. Figure 1 in Paper III describe the selection of cases and controls. Maternal 
characteristics and previous chronic disease noted at the  rst antenatal visit in MBR 
was used. 
Pre-speci ed cardiovascular, obstetric and neonatal outcome diagnoses were identi-
 ed by ICD-8 to ICD-10 codes in the NPR and parameters in MBR. The date of car-
diovascular outcome diagnoses was noted to evaluate if the outcome diagnosis also 
was present prior to the pregnancy. Data on outcome were collected from time of con-
ception to one year postpartum. Mortality date was registered as in the Cause of Death 
register. The coverage and validity of the national registries are further described in 
Paper III. The observation time was 1973-2015, which was further separated into four 
eras, since health care systems, general health, diagnostics, coding of diagnoses, and 
panorama of disease may have changed over time. 
Paper IV
The  owchart in Figure 6 show the time points when blood samples were drawn 
and health status was con rmed. Details on laboratory tests are described in Paper 
IV. Blood samples were hemoglobin, erythrocyte volume fraction, creatinine, and the 
heart biomarkers of interest; N-terminal Natriuretic Brain Peptide (NT-proBNP) and 
high sensitive cardiac Troponin T (hs-cTNT). Urine dipstick was used for ruling out 
renal disease, which might affect levels of biomarkers. If the blood test result was out 
of reference levels for non-pregnant persons, the women were contacted by phone 
and in some cases, supplementary blood samples were drawn or physical examination 
including echocardiography was performed. 
There are several laboratory test for heart biomarkers, which are in use in different 
parts of the world. We chose the ones used in daily practice at Sahlgrenska Univer-
sity Hospital, Gothenburg, well documented and in use worldwide. We compared our 
 ndings with the cut-off levels used at the lab for ruling out heart failure (NTproBNP, 
<300 ng/l) or myocardial infarction (hs-cTNT <14 ng/l) in normal population and 
with the ESC guidelines proposed normal levels (NTproBNP <125 ng/l and hs-cTNT 
<5 ng/l). We analyzed the total cohort of pre-pregnancy healthy women. We identi ed 
a subgroup of women without obesity, levothyroxine supplement, or obstetric events 
and analyzed them separately.
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heart biomarkers of interest; N-terminal Natriuretic Brain Peptide (NT-proBNP) and 
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and in some cases, supplementary blood samples were drawn or physical examination 
including echocardiography was performed. 
There are several laboratory test for heart biomarkers, which are in use in different 
parts of the world. We chose the ones used in daily practice at Sahlgrenska Univer-
sity Hospital, Gothenburg, well documented and in use worldwide. We compared our 
 ndings with the cut-off levels used at the lab for ruling out heart failure (NTproBNP, 
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a subgroup of women without obesity, levothyroxine supplement, or obstetric events 
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Statistical analyses 
In Paper I we used outcome data from a single center cohort with number of preg-
nancies as denominator, not number of women. Descriptive data were numbers and 
percentages; for normally distributed parameters mean and standard deviation or for 
non-normally distributed parameters median and interquartile range as appropriate. 
The association between complications and the two risk classi cations CARPREG I 
and mWHO was calculated with robust Poisson regression. Risk ratios (RR) and their 
95% con dence interval (CI) were used as effect sizes. We reported the applicability 
of two risk classi cations using sensitivity, speci city and area under the receiver op-
erating characteristic (ROC) curve (AUC). An AUC of 1 indicates a perfect test, while 
0.5 indicate no discriminative capacity.  In general, an AUC of 0.7 to 0.8 is considered 
acceptable. 
Paper II. Differences in cardiac complication across continuous variables (i.e., age 
and BMI at the  rst antenatal visit) were assessed with either the Student t test or the 
Mann-Whitney test (for non-normally distributed data). Categorical variables (i.e., 
smoking status, CARPREG and mWHO) were analyzed by utilizing Fisher’s Exact 
test. For identi cation of cardiac complication outcome of subsequent pregnancy in 
relation to previous pregnancy odds ratios (OR) were calculated. In total three par-
ity groups were compared (parity 1, 2, and ≥3). Three separate multivariable logistic 
regression analyses were used to detect variables predictive of cardiac complications. 
Signi cant predictors (i.e., CARPREG and mWHO score) were then used in a cross-
lagged autoregressive longitudinal analysis predicting the OR of prior cardiac com-
plication on subsequent cardiac complication controlling for CARPREG and mWHO 
score. A cross-lagged path indicates the prospective effect of one variable (e.g., CAR-
PREG) on the other (e.g., cardiac complication).
Paper III. Descriptive statistics was used with numbers and percentages, mean and 






































Figure 6. Flowchart of study protocol. gw = gestational week, ECG = electrocardiogram.
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tween CHD women and non-CHD regarding complications during pregnancy from 
time of conception up to one year postpartum. The six lesion groups were analyzed in 
comparison with their matched controls. Statistical software used was R Core Team 
(2017). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria.
Paper IV. All continuous data were controlled for normality using the Shapiro-Wilk 
test. Mean-level changes in NTproBNP and hs-cTroponinT was examined across four 
time-points. In clinical laboratory literature, a minimum of 120 samples are required 
for statistical analysis(201). Prior this analysis, the Shapiro-Wilk goodness-of- t test 
showed that NTproBNP and hs-cTroponinT levels at each of the time-points were 
not normally distributed. Therefore, these data were log transformed before analysis 
of repeated measures analysis of variance (ANOVA). Point-biserial correlation coef-
 cients for dichotomous variables were used for cut-off values of biomarkers. For sig-
ni cance testing independent T test and Mann-Whitney U test for continuous depen-
dent variables and Fisher’s Exact test for categorical variables were used. Differences 
in peripartum variables across cutoff values of NTproBNP and hs-cTroponinT were 
presented as mean ± Standard deviation (SD) or median ± interquartile range (IQR) 
as appropriate for continuous variables, and number with percentages for categorical 
variables. In addition, Bonferroni-adjusted comparisons were conducted for categori-
cal variables by using adjusted standardized residual analysis for each cell in the table. 
Statistical signi cance at p<0.05 was assumed. IBM SPSS, version 26.0, statistical 
software (SPSS, Inc; Chicago, IL) was used. A statistician, in collaboration with the 
 rst author, performed the statistical analyses in Paper I, II and IV. The analyses for 
Paper III were performed by another statistician, in collaboration with the  rst author.
Ethical considerations
The Gothenburg Regional Ethical Review Board approved the papers. Patients at the 
GUCH center gave informed consent at the visit during pregnancy to use the medi-
cal and obstetric records for outcome data for Paper I and II. Data were registered 
according to Personuppgiftslagen (PUL1998:204, registration nr 29513) in transition 
to GDPR. The cohorts from Paper I and II were included in the ethical approval for 
Paper III. In Paper III, all personal identi cation numbers were removed by Swed-
ish National Board of Health and Welfare and were replaced with a code. Due to 
ethical reasons, outcomes with less than  ve individuals in national registers are not 
presented. Participants in Paper IV signed informed consent. Pathologic  ndings ren-
dered referral to suitable health care provider. Women who had a miscarriage after the 
inclusion were excluded from further study visits in Paper IV. They were contacted 
later and offered physical examination and echocardiography. The data are reported 
for groups of participants and not for individuals. The study participants in Paper IV 
received a letter after publication with information on the result in Swedish and a link 
to the publication. The four studies complies with the Declaration of Helsinki.
Ethical approval Paper I-III: 540-11, T974-12, T022-15, T544-16, T734-17, 2020-
01178. Ethical approval Paper IV: 206-15, T114-16, T928-16, T746-17.
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tween CHD women and non-CHD regarding complications during pregnancy from 
time of conception up to one year postpartum. The six lesion groups were analyzed in 
comparison with their matched controls. Statistical software used was R Core Team 
(2017). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria.
Paper IV. All continuous data were controlled for normality using the Shapiro-Wilk 
test. Mean-level changes in NTproBNP and hs-cTroponinT was examined across four 
time-points. In clinical laboratory literature, a minimum of 120 samples are required 
for statistical analysis(201). Prior this analysis, the Shapiro-Wilk goodness-of- t test 
showed that NTproBNP and hs-cTroponinT levels at each of the time-points were 
not normally distributed. Therefore, these data were log transformed before analysis 
of repeated measures analysis of variance (ANOVA). Point-biserial correlation coef-
 cients for dichotomous variables were used for cut-off values of biomarkers. For sig-
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GUCH center gave informed consent at the visit during pregnancy to use the medi-
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inclusion were excluded from further study visits in Paper IV. They were contacted 
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for groups of participants and not for individuals. The study participants in Paper IV 
received a letter after publication with information on the result in Swedish and a link 
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The distribution of live birth, miscarriages, legal abortions and 
stillbirth according to CHD diagnosis is shown below (Paper I, 
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Figure 7. Distribution of legal abortions, miscarriages, intrauterine deaths and live birth (born). 
Total number of pregnancies on Y-axis. Ao, aortic. Combined AS/AR, aortic stenosis aortic regur-
gitation. HCM hypertrophic cardiomyopathy. AVSD, atrioventricular septal defect. Pulm+tricusp, 
pulmonary or tricuspid valve disease. Aortic, aortopathy.
Outcome data of the total cohort and of pregnancies in women below and above 35 
years are shown in Table 6.
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Table 6. Outcome of cardiac, obstetric and neonatal complications by age above or below 
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Table 6. Outcome of cardiac, obstetric and neonatal complications by age above or below 
35 years in our single center cohort. (Paper I Table 2, with permission from Elsevier).
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When evaluating two risk classi cations we found higher sensitivity with mWHO and 
higher speci city with CARPREG I. The area under the receiver operating character-
istic curve (AUC) had values that are generally considered “good” for CARPREG I 






















86 44 0.65 68 44 0.56 64 44 0.54
Sens, sensitivity. Spec, specificity. AUC, area under the ROC curve. 
Table 7. Appendix 3, Paper I (permission from Elsevier)
Figure 2 a and b in Paper I show that complications do occur also in pregnancies with 
low scores of both classi cations. When analyzing the cohort further we found that 
multiple complications could occur in the same pregnancy, Figure 8.
Figure 8. Distribution of complications.
Paper II
The odds ratio for cardiac complication outcome of the second pregnancy compared 
to the  rst was 5.47 (95% CI 1.76–16.94), adjusted for age, body mass index and 
smoking habits, if the woman remained in the same risk classi cation score. Figure 
2 in Paper II is a  owchart of the cardiac outcome of pregnancies. Table 2 in Paper 
II show the risk classi cations for women with and without cardiac complications. 
Standardized regression coef cients on the association between risk classi cations 
45
and cardiac complication at different parity time points were calculated in an au-
toregressive cross-lagged longitudinal model, adjusted for age, BMI and smoking. 
Standardized regression coef cients indicate how strong the association is between 
the directions of two parameters, from 0 to 1, where higher number is a stronger as-
sociation. There was an association of the same outcome, i.e to have or have not a 
cardiac complication during the second pregnancy if there was, or was not, a cardiac 
complication during the  rst (standardized coef cient 0.38). There was no signi cant 
association of cardiac complications between second pregnancy and 3rd-8th pregnancy. 
CARPREG I score during the second pregnancy predicted cardiac complication at 
the 3rd-8th pregnancy (standardized coef cient 0.70), but not at the second pregnancy. 
There was no signi cant association between CARPREG I score the  rst pregnancy 
and cardiac complications the  rst or second pregnancy. There was no association for 
CARPREG I scoring between the second and third pregnancy, indicating that there 
was a change in score after the second pregnancy. Prior cardiovascular history is one 
parameter in that scoring system, and for example arrhythmia increase by time in the 
CHD population. There was no signi cant association between mWHO classi cation 
and  rst or second pregnancy cardiac complications. mWHO score at the 3rd- 8th preg-
nancy was associated with cardiac complication at the same pregnancies (standard-
ized regression coef cient 0.50). The mWHO classi cation remained the same for 
every pregnancy, which is to be expected since it is based largely on type of lesion. 
The follow up data on two years postpartum were without maternal deaths. During 
two years of follow up 13 of the 307 women had a heart intervention. Nine of them 
were ASD closures. Within two years, six women (1.9%) had heart failure and  ve of 
them were in high risk class (mWHO class III or IV) at their latest pregnancy.
Paper III
There were 6´131 women with CHD and 158´343 age-matched women without CHD 
in their  rst singleton pregnancy. The number of women with CHD who become 
pregnant has doubled from the  rst era (1973-1986) to modern era (2007-2015), see 
Table 1 Paper III. The proportion of severe CHD-diagnoses among them has also 
increased. Lesion class 6 (“other”) was the most common diagnostic group in the lat-
est era followed by lesion class 4 (VSD). Lesion class 6 (“other”) include left-sided 
valvular disease, but the registries do not include information on degree of severity. 
Lesion class 5 (ASD) were 40% of the CHD in the earliest era which decreased to 
18% in the latest era. 
Lesion class 1 and 2, which are considered “complex”, were 5.9% of the CHD popu-
lation in the earliest era to be compared with 8.1% in the latest era. During the same 
time age at  rst pregnancy increased. In the CHD cohort age increased from 22.6 to 
27.4 years and the control population were matched for age. In the  rst era maternal 
mean weight at  rst antenatal visit was 60 kg in both cohorts, which increased to 67 
kg in the latest era. Smoking decreased from 21% to 6%. 
Cardiac complication rates were low in absolute numbers in both cohorts, however 
higher OR for CHD women (Paper III, Table 2). The cardiac complications in the 
non-CHD cohort were to a high degree “new onset” while it was more common for 
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every pregnancy, which is to be expected since it is based largely on type of lesion. 
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two years of follow up 13 of the 307 women had a heart intervention. Nine of them 
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increased. Lesion class 6 (“other”) was the most common diagnostic group in the lat-
est era followed by lesion class 4 (VSD). Lesion class 6 (“other”) include left-sided 
valvular disease, but the registries do not include information on degree of severity. 
Lesion class 5 (ASD) were 40% of the CHD in the earliest era which decreased to 
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mean weight at  rst antenatal visit was 60 kg in both cohorts, which increased to 67 
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higher OR for CHD women (Paper III, Table 2). The cardiac complications in the 
non-CHD cohort were to a high degree “new onset” while it was more common for 
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CHD women to have had a complication before (Paper III, Figure 2a, b). All-cause 
mortality within 42 days postpartum was higher in CHD than in non-CHD, however, 
with low absolute numbers (Paper III, Figure 5). 
The obstetric complications preeclampsia, gestational diabetes and postpartum hem-
orrhage were more prevalent in the CHD cohort, compared with non-CHD (Paper III, 
Figure 3). Previous miscarriage was also more frequent in the CHD cohort. 
The neonatal complications were more prevalent in CHD pregnancies compared with 
non-CHD, as shown in Figure 5, Paper III. All studied parameters on neonatal com-
plications (stillbirth, low birth weight, very low birth weight, small gestational age, 
preterm, very preterm and low Apgar score) had higher ORs in the CHD cohort. 
Paper IV
The highest median levels of NT-proBNP were found in 10-12 gw samples. When di-
viding NTproBNP with EVF there was no signi cant difference between the four time 
points, indicating that the “concentration” of NTproBNP remains the same through-
out pregnancy. The glomerular  ltration rate is highest at 20-25 gw compared to the 
other time points, which coincided with the lowest NTproBNP levels. In the subgroup 
without any obstetric events, the 95th percentile was 155 ng/l, which is below the level 
used as cut-off for ruling out heart failure of 300 ng/l (Paper IV, Table 2 and Figure 
2). Women with NTproBNP <125 ng/l at the peripartum measurement had higher 
glomerular  ltration rate, had oxytocin only as postpartum hemorrhage prophylaxis 
and had more often spontaneous vaginal deliveries compared with women with levels 
>125 ng/l (Paper IV, Table 4). There were  ve women with NTproBNP levels above 
300 ng/l on any occasion without signs or symptoms of heart failure. One outlier with 
990 ng/l at the peripartum measurement had fever during delivery. She was contacted 
for physical examination and had repeated blood samples with normal  ndings. The 
highest levels of hs-cTNT were at the peripartum measurement. There were three 
women with hs-cTNT levels above 14 ng/l (range 14.4 ̶ 30.6); two women with un-
complicated vaginal deliveries and one woman with fever (Paper IV, Table 3 and Fig-
ure 3). Time from delivery to blood test was associated with hs-cTNT >5.0 ng/l (Paper 
IV, Table 4). There were three women with preeclampsia and they had NTproBNP 
<125 ng/l on all four time points. Normal levels of NTproBNP and hs-cTNT during 
pregnancy, peripartum and postpartum are shown in Figure 9. 
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Figure 9. NTproBNP and hs-cTNT during pregnancy, peripartum and postpartum. 
“Selected” include women with spontaneous conception, BMI <35 at fi rst antenatal 
visit, a normal pregnancy and delivery i.e. no miscarriage, no treatment with levothy-
roxine, no hypertensive disorders of pregnancy, not more than 1+ proteinuria on one 
occasion, and a vaginal non-assisted delivery at term without complications and no 
postpartum hemorrhage >1000 ml. Published with permission from BMJ Journals.
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Paper I, II and III address issues discussed in clinical prac-
tice. Young women with CHD ask questions about possible 
risks for themselves and their future children when consid-
ering pregnancy. We found the absolute risk of pregnancy-
associated complications to be low and the use of risk classi-
 cations to be reasonable. If the woman had a  rst pregnancy 
without cardiac complications and if she still is in the same 
risk class there is a high probability that a second pregnancy 
will be uneventful. 
Being single center studies (Paper I and II) the risk of misclassi cation of CHD di-
agnosis or outcome data is low. We cannot exclude the possibility of referral bias, 
which would indicate a lower risk among the general CHD population. In Sweden 
approximately 35 000 adults have a CHD diagnosis of whom 16 000 are included in 
the national SWEDCON register, indicating that they are regularly seen by a CHD 
specialist(3). In different regions in the world, the proportion of CHD patients attend-
ing specialized care the rate may be even lower, depending on health care system and 
economic situation. However, the distribution of the study population includes both 
low- and high-risk classi cations. In register studies (Paper III) there is a risk of mis-
classi cation of outcome diagnosis codes but that risk is the same for the entire study 
population. Validation studies of cardiac diagnoses in Swedish national registers have 
shown high validity(202, 203).   
There are different rates reported in publications on pregnancy-associated compli-
cations depending on the methods of the studies. The spectrum of CHD diagnoses 
included in the reports affect outcome, as the cohorts are different in tertiary centers 
compared to primary centers. Patients often have multiple CHD diagnoses and some-
times a combination of CHD and acquired heart disease. Moreover, access to health 
care vary between countries and socioeconomic structures. Since there are many dif-
ferent CHD diagnoses, they are often categorized into a limited number of hierar-
chal classes, and the classi cation systems have different origin. Several publications 
report pregnancies both in women with congenital and with acquired heart disease. 
The de nition of outcomes in different publications will further make comparisons 
dif cult. Separating outcome as cardiac, obstetric and neonatal complications may 
overestimate the risk for the total population, since several complications can occur 
in the same woman. Sometimes number of women is reported in publications and 
sometimes number of pregnancies. When number of pregnancies is reported the same 
women may be included several times, which may affect the outcome depending on 
the study population. Absence of any complications is seldom reported, but is of inter-
est for the patients. 
Paper IV is a prospective study on heart biomarkers. The results are valuable in clini-
cal practice if a previously healthy pregnant woman complains of chest pain or dys-
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pnea. Elevated heart biomarker levels request further attention, but it is noteworthy 
that a handful of women had elevated levels without having a cardiac diagnosis. We 
did not investigate cut-off levels of biomarkers for the diagnosis of heart failure or 
myocardial infarction in pregnant women, but normal levels found in healthy women 
during and after pregnancy.
Paper I
Complications during pregnancy in a single CHD center
Paper I is a descriptive analysis of cardiac, obstetric and neonatal complications dur-
ing pregnancy in a single center cohort. We found similar cardiac complication rates 
as in previous multicenter studies(133, 136, 151). Heart failure was found in 4% to be com-
pared with 1.6% in the ZAHARA study on 1´802 women in the Netherlands and Bel-
gium with CHD, and 6.2% in the second ROPAC cohort and comparable with 4.1% in 
the  rst ROPAC cohort(133, 134, 136). The ROPAC register include women from both low 
and high income countries and there is a possibility that centers include women with 
more complex disease at a higher degree than very simple defects, which may explain 
the differences. We found arrhythmia in 6%, which is similar to 4.7% in the ZAHARA 
cohort with a similar de nition of arrhythmia as being clinically signi cant. In some 
studies ECG documentation or hospitalization for arrhythmia is required as the de ni-
tion, why their reports of arrhythmia may be lower. Heart failure and arrhythmia are 
described in literature as more frequent from late second trimester to early postpar-
tum(86, 134, 142). We did not note the timing of complications. Thromboembolic events 
were rare (0.4%), not associated with mechanical valve prosthesis. In our cohort there 
was only one pregnancy with mechanical valve and few women were on more potent 
anticoagulation therapy than acetylsalicylic acid. Mechanical valve was found to be 
a risk factor in several publications for both mother and offspring(86, 133, 152, 204). In our 
population, which was a medium risk population in a good-standard health care sys-
tem, we had one maternal death (0.2%). Depending on study population there are re-
ports of 0.6% to 2.7% maternal mortality with considerably higher risk in women with 
pulmonary arterial hypertension or Eisenmenger syndrome(136, 141, 175). Cardiac com-
plications are prevalent in the CHD population also without pregnancy, at increasing 
incidence by age(205-207). However, non-pregnant CHD-women are not suitable as con-
trols since they probably are a different cohort; younger, more symptomatic or with 
more complex disease, for example. Some of them are advised against pregnancy or 
choose not to become pregnant due to other medical risk factors. 
The most common obstetric complication, besides miscarriage, was postpartum hem-
orrhage with 8%, which is at the same level as for our obstetric institution of 5-10%. 
Preeclampsia was found in 3.4% to be compared with 3% in the ROPAC, and 4.4% in 
the ZAHARA study(133, 136). Udholm et al found preeclampsia to be more common in 
patients with an ASD diagnosis (not indicated whether they were operated or not) in a 
nationwide register study with 6.7% compared with 2.3% in control population. The 
ASD patients had more often become pregnant with assisted reproductive technology, 
which is a risk factor for preeclampsia(169).
The most severe neonatal complication is perinatal death. When excluding the peri-
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after 22 gestational weeks, to be compared with 0.4% in the Swedish population. In 
the ZAHARA cohort, with exclusively CHD pregnancies, 3.8% stillbirth and infant 
mortality was found. They included deaths from 20 gw up to one year of age, which 
may be one explanation of their higher rate(25, 133). Our rate of preterm birth (8%) was 
lower and low birth weight (6%) was lower or similar to other publications of 14-
17% and 3.7-14% respectively(133, 151). The familial recurrence rate of cardiac defects 
(2.9%) was not analyzed according to maternal diagnoses and we did not analyze the 
recurrence rate for paternal cardiac defects. The ESC guidelines reported higher rates 
and the dif culties with recurrence rate reports were discussed in the Introduction(67). 
Maternal age
Advanced maternal age (in obstetric literature usually de ned as age above 35 or 40 
years) during pregnancy is associated with obstetric and neonatal complications in 
the general population(27, 208-211). We found no signi cantly increased risk for cardiac, 
obstetric or neonatal complications in our cohort of CHD women above 35 years of 
age compared with 35 years or below. The group above 35 years comprised of 15% 
of the total cohort. When adjusting for mWHO class, age above 35 years had a rela-
tive risk of 1.07 (95% CI 1.01–1.14) for cardiac complications, but not for obstetric 
or neonatal complications. 
Our analyses were made on composite outcomes. Cardiac complications increase 
by age in the total CHD-population that make the impact of pregnancy dif cult to 
separate from the natural course. In accordance with our  ndings, the CARPREG II 
did not  nd maternal age to be predictive of cardiac event(135). A Danish nationwide 
register-based study on CHD and controls separated age in 5-year intervals. The au-
thors found age already from above 30 years to be associated with preterm birth and 
small for gestational age for both groups, with CHD women having an increased risk 
compared with non-CHD(196). Since women 30-35 years were in the younger group 
in our study, it may have equalized the two groups. Maternal complications were not 
reported in the Danish study. There was a high correlation between maternal compli-
cation and offspring complication in the ZAHARA population (r=0.85, p=0.002(133). 
One third of the neonatal complications in our study were in women with cardiac 
complications. CHD women were more often born preterm themselves in a Swedish 
nationwide register-based study and gave birth to preterm neonates, why genetic and 
other factors, besides age, may play a role in neonatal complications(179).
In conclusion, maternal age above 35 years per se was not a risk factor for adverse 
events during pregnancy in our cohort, but the risk for cardiac problems to occur in-
crease by age in the CHD population.
 
Risk classifi cations
We tested the performance of two risk classi cations (CARPREG I and mWHO) in 
our single center cohort(151, 187). We chose not to evaluate the ZAHARA score, since it 
is more complex and was found inferior to mWHO by Balci et al in a CHD cohort(188). 
We agree with the authors of the ZAHARA that the predictor “AV-valve regurgita-
tion” is associated with poor ventricular function and may not be a predictor on its 
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own(133). We found mWHO to have higher sensitivity and CARPREG I to have higher 
speci city for all complications, but the diagnostic accuracy was moderate for both 
classi cations in assessing cardiac risk (CARPREG I 0.71 and mWHO 0.65). Evalua-
tions of risk classi cations in different cohorts have found mWHO to be better in pre-
dicting cardiac events(188-192). Four of them were on CHD women exclusively while the 
Spanish study included 31% non-CHD. Wang et al compared CARPREG I, ZAHARA 
and mWHO  in a meta-analysis and found CARPREG I to be inferior to the two oth-
ers(195). Van Hagen found mWHO to be moderately discriminative (AUC 0.71) and 
combining with pre-pregnancy history added prognostic value in the ROPAC register 
population(140). CARPREG II, together with the three others, was evaluated recently in 
a CHD cohort of 100 patients and did not perform better than the others(194). Balci et 
al found AUC <0.6 for CARPREG I, ZAHARA and mWHO for offspring risk, which 
was similar to our  ndings and indicate that these risk classi cations have better per-
formance for cardiac events.  
The above-mentioned differences in selection of cohorts and de nitions of outcome 
make evaluation of risk classi cation a challenge. A review on different risk clas-
si cations found that none of the classi cation systems has both high sensitivity and 
speci city and pointed out the methodological issues(193). Using AUC is a way to mea-
sure performance of classi cations and is a combination of sensitivity and speci city. 
Sensitivity,  nding the ones with expected complications, may be the better measure-
ment for planning health care service. Speci city, identifying presumably low risk 
pregnancies, may be more interesting for the individual counselling. All prevalent 
risk classi cations are useful to some extent when giving advice to CHD women and 
when planning health care resources. However, the performances of the risk assess-
ments are rather low and indicate the need for centralized expertise and experience as 
a complement. A reasonable approach is using a combination of risk classi cations, 
with mWHO as a lesion-speci c base, and predictors from CARPREG and ZAHARA 
in multidisciplinary conferences(40, 175, 193).  
Paper II
Parity
The number of children that women give birth to will be in uenced by many fac-
tors; socioeconomic, health care systems, inter-personal relations, own health issues 
among others. Maternal age and parity are naturally linked. We chose to include all 
pregnancies >12 gestational weeks. We classi ed women according to CARPREG I 
and mWHO and analyzed the effect of parity on cardiac complications during preg-
nancy. Age was not associated with cardiac complications, while high risk class was 
associated with unfavorable cardiac outcome. If the woman remained in the same 
risk class in the second pregnancy compared to the  rst, the age-adjusted OR was 5.5 
(95% CI, 1.8-16.4) for the same cardiac outcome. Our results are similar to Gelson 
et al who found a lower proportion of cardiac complications in the second pregnancy 
compared with the  rst, however not statistically signi cant. They included 77 wom-
en with congenital and acquired heart disease without classifying in risk scores and 
154 controls of similar age(212). 
50
after 22 gestational weeks, to be compared with 0.4% in the Swedish population. In 
the ZAHARA cohort, with exclusively CHD pregnancies, 3.8% stillbirth and infant 
mortality was found. They included deaths from 20 gw up to one year of age, which 
may be one explanation of their higher rate(25, 133). Our rate of preterm birth (8%) was 
lower and low birth weight (6%) was lower or similar to other publications of 14-
17% and 3.7-14% respectively(133, 151). The familial recurrence rate of cardiac defects 
(2.9%) was not analyzed according to maternal diagnoses and we did not analyze the 
recurrence rate for paternal cardiac defects. The ESC guidelines reported higher rates 
and the dif culties with recurrence rate reports were discussed in the Introduction(67). 
Maternal age
Advanced maternal age (in obstetric literature usually de ned as age above 35 or 40 
years) during pregnancy is associated with obstetric and neonatal complications in 
the general population(27, 208-211). We found no signi cantly increased risk for cardiac, 
obstetric or neonatal complications in our cohort of CHD women above 35 years of 
age compared with 35 years or below. The group above 35 years comprised of 15% 
of the total cohort. When adjusting for mWHO class, age above 35 years had a rela-
tive risk of 1.07 (95% CI 1.01–1.14) for cardiac complications, but not for obstetric 
or neonatal complications. 
Our analyses were made on composite outcomes. Cardiac complications increase 
by age in the total CHD-population that make the impact of pregnancy dif cult to 
separate from the natural course. In accordance with our  ndings, the CARPREG II 
did not  nd maternal age to be predictive of cardiac event(135). A Danish nationwide 
register-based study on CHD and controls separated age in 5-year intervals. The au-
thors found age already from above 30 years to be associated with preterm birth and 
small for gestational age for both groups, with CHD women having an increased risk 
compared with non-CHD(196). Since women 30-35 years were in the younger group 
in our study, it may have equalized the two groups. Maternal complications were not 
reported in the Danish study. There was a high correlation between maternal compli-
cation and offspring complication in the ZAHARA population (r=0.85, p=0.002(133). 
One third of the neonatal complications in our study were in women with cardiac 
complications. CHD women were more often born preterm themselves in a Swedish 
nationwide register-based study and gave birth to preterm neonates, why genetic and 
other factors, besides age, may play a role in neonatal complications(179).
In conclusion, maternal age above 35 years per se was not a risk factor for adverse 
events during pregnancy in our cohort, but the risk for cardiac problems to occur in-
crease by age in the CHD population.
 
Risk classifi cations
We tested the performance of two risk classi cations (CARPREG I and mWHO) in 
our single center cohort(151, 187). We chose not to evaluate the ZAHARA score, since it 
is more complex and was found inferior to mWHO by Balci et al in a CHD cohort(188). 
We agree with the authors of the ZAHARA that the predictor “AV-valve regurgita-
tion” is associated with poor ventricular function and may not be a predictor on its 
51
own(133). We found mWHO to have higher sensitivity and CARPREG I to have higher 
speci city for all complications, but the diagnostic accuracy was moderate for both 
classi cations in assessing cardiac risk (CARPREG I 0.71 and mWHO 0.65). Evalua-
tions of risk classi cations in different cohorts have found mWHO to be better in pre-
dicting cardiac events(188-192). Four of them were on CHD women exclusively while the 
Spanish study included 31% non-CHD. Wang et al compared CARPREG I, ZAHARA 
and mWHO  in a meta-analysis and found CARPREG I to be inferior to the two oth-
ers(195). Van Hagen found mWHO to be moderately discriminative (AUC 0.71) and 
combining with pre-pregnancy history added prognostic value in the ROPAC register 
population(140). CARPREG II, together with the three others, was evaluated recently in 
a CHD cohort of 100 patients and did not perform better than the others(194). Balci et 
al found AUC <0.6 for CARPREG I, ZAHARA and mWHO for offspring risk, which 
was similar to our  ndings and indicate that these risk classi cations have better per-
formance for cardiac events.  
The above-mentioned differences in selection of cohorts and de nitions of outcome 
make evaluation of risk classi cation a challenge. A review on different risk clas-
si cations found that none of the classi cation systems has both high sensitivity and 
speci city and pointed out the methodological issues(193). Using AUC is a way to mea-
sure performance of classi cations and is a combination of sensitivity and speci city. 
Sensitivity,  nding the ones with expected complications, may be the better measure-
ment for planning health care service. Speci city, identifying presumably low risk 
pregnancies, may be more interesting for the individual counselling. All prevalent 
risk classi cations are useful to some extent when giving advice to CHD women and 
when planning health care resources. However, the performances of the risk assess-
ments are rather low and indicate the need for centralized expertise and experience as 
a complement. A reasonable approach is using a combination of risk classi cations, 
with mWHO as a lesion-speci c base, and predictors from CARPREG and ZAHARA 
in multidisciplinary conferences(40, 175, 193).  
Paper II
Parity
The number of children that women give birth to will be in uenced by many fac-
tors; socioeconomic, health care systems, inter-personal relations, own health issues 
among others. Maternal age and parity are naturally linked. We chose to include all 
pregnancies >12 gestational weeks. We classi ed women according to CARPREG I 
and mWHO and analyzed the effect of parity on cardiac complications during preg-
nancy. Age was not associated with cardiac complications, while high risk class was 
associated with unfavorable cardiac outcome. If the woman remained in the same 
risk class in the second pregnancy compared to the  rst, the age-adjusted OR was 5.5 
(95% CI, 1.8-16.4) for the same cardiac outcome. Our results are similar to Gelson 
et al who found a lower proportion of cardiac complications in the second pregnancy 
compared with the  rst, however not statistically signi cant. They included 77 wom-
en with congenital and acquired heart disease without classifying in risk scores and 
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In large registry or multicenter studies parity is either not commented, or the women 
are dichotomized as being primiparous or multiparous(133, 135, 136, 140, 191). Some publica-
tions separate parity into more than two categories(139, 151, 188, 190, 192). However, none of 
the publications report an association between parity and cardiac outcome. Our data 
were collected retrospectively but during a certain time period. Primiparous women 
in our dataset might become pregnant again after data analysis, why the data cannot 
be interpreted as reproductive behavior in CHD women. 
It is not surprising that women with an uncomplicated  rst pregnancy chose to be-
come pregnant again. However, also women with cardiac complication chose to 
become pregnant again. There was an association between complication at the sec-
ond pregnancy and change in mWHO class. A possible interpretation is worsening 
of ventricular function at the second pregnancy and change to higher mWHO class. 
Before every pregnancy, it is reasonable to assess whether the woman has changed 
risk class and need counselling accordingly. We analyzed the effect of parity in the 
total cohort; however, there might be lesions within the cohort where parity actually 
is a risk factor. We had few women with systemic right ventricle, women with poor 
systemic ventricular function and high-risk aortopathies for example, in whom parity 
might add to the progress of their lesion(159). We did not analyze obstetric or neonatal 
complications. Maternal age seem to be more important than parity in publications 
on obstetric events in normal population(209-211). In conclusion, CHD-women without 
cardiac complications during the  rst pregnancy can anticipate the same outcome of a 
second pregnancy if she is stable. The need for cardiac interventions within two years 
after pregnancy is low. 
Paper III
Changes in maternal characteristics by time
In the time period from 1973 to 2015 the number of women with CHD who gave birth 
doubled. Survival in children with CHD has increased and when reaching adult age 
family planning become important(4-6). Diagnostics of CHD has become better, with 
echocardiography in the 1990´s, why previously undiagnosed lesions can be found. 
We accepted women as CHD cases also when they got the diagnosis after pregnancy, 
since the defect was present during pregnancy. There may be women in the control 
population in the earlier eras who had an undiagnosed lesion, but since we accepted 
diagnoses found in the NPR also after pregnancy, we consider that risk to be low. 
Mean age at  rst CHD diagnosis in the cohort decreased during the period indicat-
ing that some of the women were diagnosed after pregnancy, especially in the earlier 
eras. The most common lesion in women giving birth in the earliest era was ASD. The 
proportion of ASD in the lesion groups decreased by time. The ICD code (Q21.1) for 
ASD is the same as for patent foramen ovale (PFO), which do not have hemodynamic 
impact. There may be women who got their ASD/PFO diagnosis after giving birth, at 
an older age. If the proportion of PFO in ICD-code Q21.1 is high, this would dilute 
the risk for hemodynamic complications. 
In the earlier era only one  fth of the women had the CHD diagnosis before pregnancy 
which increased to 83% known CHD diagnosis before pregnancy in the latest era. 
53
Late pregnancy assessment has been suggested to predict cardiac complications(135). 
No prior cardiac intervention was associated with cardiac complications in the same 
study. In their cohort 53% of the women had a prior cardiac intervention while in our 
register cohort only 10% in the early, and 28% in the late era were intervened on. This 
suggests that their cohort was selected with more advanced CHD. Between 1973 and 
2015 maternal age at  rst pregnancy and weight at  rst antenatal visit has increased, 
which is associated with obstetric and neonatal complications such as preeclampsia, 
PTB and SGA(91, 94, 95, 119, 196). 
 
Swedish register data on cardiac complications in CHD pregnancy
The absolute risk of cardiac complications and maternal death were low, but com-
pared with age-matched women the odds ratios were high, since cardiac complica-
tions are unusual in young women. For non-CHD women the cardiac complication 
mostly occurred as a new onset complication, while CHD women sometimes had 
experienced a cardiac complication before pregnany. Outpatient visits have been 
registered from 2001 and onwards why pre-existing diseases without hospitalization 
before that may be underreported, however we used both NPR and MBR for previ-
ous maternal diagnoses. The missing data would likely be similar for both groups. A 
Canadian discharge note register used a composite “maternal morbidity index” and 
found that CHD women more often had at least two previous morbidities compared 
with non-CHD. This index include previous cardiac disease why an association is to 
be anticipated(168).
Heart failure affected very few of the primiparous CHD-women during pregnancy 
in our cohort, which is far below numbers in single center and multicenter reports of 
1.6-6.2%(133, 136). During one-year follow up after pregnancy the absolute rate of heart 
failure was similarly low in both cohorts, however with higher OR in CHD vs non 
CHD women. Our missing data on follow up would be low in contrast to a Californian 
discharge-note register with 14% missing data on 30 days and 10% at one year(198). 
In their study heart failure was reported in <0.5% of CHD during hospital stay. Most 
studies include both primiparous and multiparous women and multiparity is not con-
sidered to be a predictor for adverse outcome in guidelines. The multicenter stud-
ies ZAHARA and ROPAC and the Canadian discharge note register contain 45-50% 
primiparous women. Discharge note registers (without personal identi cation) and 
multicenter studies may contain several pregnancies in the same woman. A woman 
with previous diagnosis of heart failure is likely to be registered with heart failure 
diagnosis every pregnancy which could affect the reported outcome. 
The Canadian register reported complications as a composite (Maternal Morbidity 
Outcome Indicator), where heart failure rate was not reported separately. An Amer-
ican discharge note register study found heart failure diagnosis in 0.96% of CHD 
women compared with 0.03% in non-matched non-CHD women(197). The most com-
mon cardiac complication in their study was arrhythmia with 2.6% of CHD and 0.2% 
of non-CHD women. In our CHD cohort, less than one percent had arrhythmia dur-
ing pregnancy, while just over two percent had a previous diagnosis of arrhythmia. 
There is a possibility in register studies that previous diagnoses will be registered 
even though they did not occur during the time of pregnancy and delivery. Maternal 
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all-cause mortality during pregnancy and 42 days postpartum in primiparous women 
is low in both CHD and non-CHD cohorts in a Swedish setting. In comparison, an 
American discharge note register found in-hospital maternal death of 0.15% in CHD 
women and non-adjusted OR 18.3(197). The mortality rate may be even higher in areas 
with low health care services(21). 
Swedish register data on obstetric and neonatal complications in CHD preg-
nancy
Preeclampsia was shown to be more common in ASD patients compared with con-
trols in a Danish nationwide register study(169). They found 6.7% of ASD women vs 
2.3% controls with preeclampsia. Our preeclampsia rate was just under 5% vs 4% for 
CHD vs non CHD and the only lesion group with signi cantly higher OR was group 
6 (“other”), not the ASD group. We did not adjust for ART in our study, which is as-
sociated with higher incidence of preeclampsia, while they found ART to be more 
common in ASD women compared with controls. When searching for causes of pre-
eclampsia maternal cardiac disease has been proposed as a possible mechanism(213). 
This mechanism cannot be con rmed by our study, since one would then expect much 
higher rates in CHD women. Gestational diabetes was twice as common in CHD 
compared with non-CHD. Gestational diabetes entails an increased risk of developing 
diabetes mellitus type II that is associated with morbidity and mortality(214, 215). 
Preterm birth was studied in a Canadian register study where 13.9% in CHD women 
vs 7.4% in non-matched controls had singleton preterm birth <37 gw(168). We had 
similar rates of preterm births as Josefsson et al, who found preterm birth in 8.7% 
of “simple” CHD compared with 6.2% in non-CHD. In their “complex” group, cor-
responding to our lesion group 1 and 2, 14.9% gave preterm birth, which is similar 
to our two lesion groups(179). Low birth weight <2500 g had an OR above 1.0 in all 
our lesion groups, while mean birth weight was higher in CHD lesion group 2, 4 and 
6 compared with controls. This indicates a variation between individuals within the 
lesion groups, which might be addressed by going into detail of the diagnoses, by ad-
justing for maternal comorbidities and for socioeconomic factors. Perinatal death was 
similar to the Canadian study (0.8% vs 0.2%), however they considered their numbers 
to be underreported(168). 
The prevalence of cardiac malformations in the neonate was over four times as high in 
CHD women compared with controls in our study. We did not analyze if the cardiac 
malformation was the same as in the mother or if there were concomitant syndromes. 
Patients with autosomal dominant hereditary syndromes were not excluded. Oyen 
et al found a relative risk of recurrence of 3.4 to 79.1 depending on the  rst-degree 
relative´s cardiac defect, with an over-all relative risk of  8.15 (95% CI, 6.95-9.55) for 
the same heart defect phenotype(12). The lowest risk of recurrence in our study was in 
the ASD lesion group and the highest in the conotrunchal lesion group.
In conclusion, women with CHD have higher probability of cardiac, obstetric and 
neonatal complications during pregnancy compared to women without CHD. How-
ever, the absolute risk for the total cohort is low.  
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Paper IV
NTproBNP during and after pregnancy in healthy women.
We studied a pre-pregnancy healthy cohort, to the best of our knowledge larger than 
reported before, with serial measurements of heart biomarkers during pregnancy, peri-
partum and at 6 months postpartum. Although cardiac output was higher in the second 
trimester compared with 6 months postpartum (5.6 vs 4.4 l/min, 27% change, unpub-
lished data), NTproBNP levels were the lowest at the second trimester measurement. 
Hemodilution and glomerular  ltration rate were the highest in the second trimester. 
We believe that this re ect the low NTproBNP levels seen in mid-pregnancy. The high-
est levels of NTproBNP during pregnancy were found in the  rst trimester with levels 
not signi cantly different from 6 months postpartum. The hemodynamic changes with 
hemodilution were reported in a systematic review to be increased by 8% in the  rst 
trimester and by 23% in the second trimester compared with non-pregnant reference 
levels(33). In our study, EVF was 3% lower in the  rst, and 13% lower in the second 
trimester compared to 6 months postpartum. We did not measure third trimester levels 
of NTproBNP why comparison with other studies including third trimester cannot be 
done, but  rst and second trimester levels are comparable with others(42, 76, 77).
The peripartum measurements 17-34 hours after delivery can be compared with two 
previous reports on measurements 2-6 days and <48 h after delivery(42, 77). Both found 
considerably higher levels of NTproBNP post-delivery with median 127 (5th-95th per-
centile 22-396) and median 107 (range 61-202) compared with our median 44 (range 
5-990) in the total cohort. One difference between the two studies and ours was the 
rate of cesarean section, which was 47% in the Umazume and 33% in the Burlingame 
study, while our CS rate was 15%. Cesarean section (not speci ed whether acute or 
planned) was found to result in higher NTproBNP levels day 3 postpartum compared 
with vaginal delivery in a study on 78 healthy women(216).  
A related biomarker, BNP, has been studied. No change in BNP levels between trimes-
ters were found but sample size was low and the reference group were non-pregnant 
controls. All had BNP levels below a cut-off level of 100 ng/l for heart failure(80, 83). 
When comparing BNP to NTproBNP the latter is more affected by renal function. 
In our unpublished data of the total cohort we found mean EVF 0.36 in vaginal and 
0.32 in CS deliveries. The volume shift patterns post-delivery may differ between 
vaginal and CS deliveries. NTproBNP levels in relation to EVF were stable, without 
signi cant changes during pregnancy, peripartum and 6 months postpartum, which in-
dicate that a presumably higher NTproBNP production with increased cardiac output 
during pregnancy is balanced with hemodilution and increased glomerular  ltration. 
Hopkins et al found a correlation between hypoxia (which cause high EVF) and el-
evated NTproBNP(68). On the other hand, in a cohort of blood donors NTproBNP was 
lower with higher hemoglobin after adjusting for sex and age. EVF was not reported 
but was probably not elevated since the subjects were healthy, however only 3% were 
women aged 18-39 years(53). One explanation might be that the NTproBNP levels 
were not adjusted for creatinine. Elevated creatinine, which would increase NTproB-
NP levels, is associated with low hemoglobin(217). BMI increased between  rst and 
54
all-cause mortality during pregnancy and 42 days postpartum in primiparous women 
is low in both CHD and non-CHD cohorts in a Swedish setting. In comparison, an 
American discharge note register found in-hospital maternal death of 0.15% in CHD 
women and non-adjusted OR 18.3(197). The mortality rate may be even higher in areas 
with low health care services(21). 
Swedish register data on obstetric and neonatal complications in CHD preg-
nancy
Preeclampsia was shown to be more common in ASD patients compared with con-
trols in a Danish nationwide register study(169). They found 6.7% of ASD women vs 
2.3% controls with preeclampsia. Our preeclampsia rate was just under 5% vs 4% for 
CHD vs non CHD and the only lesion group with signi cantly higher OR was group 
6 (“other”), not the ASD group. We did not adjust for ART in our study, which is as-
sociated with higher incidence of preeclampsia, while they found ART to be more 
common in ASD women compared with controls. When searching for causes of pre-
eclampsia maternal cardiac disease has been proposed as a possible mechanism(213). 
This mechanism cannot be con rmed by our study, since one would then expect much 
higher rates in CHD women. Gestational diabetes was twice as common in CHD 
compared with non-CHD. Gestational diabetes entails an increased risk of developing 
diabetes mellitus type II that is associated with morbidity and mortality(214, 215). 
Preterm birth was studied in a Canadian register study where 13.9% in CHD women 
vs 7.4% in non-matched controls had singleton preterm birth <37 gw(168). We had 
similar rates of preterm births as Josefsson et al, who found preterm birth in 8.7% 
of “simple” CHD compared with 6.2% in non-CHD. In their “complex” group, cor-
responding to our lesion group 1 and 2, 14.9% gave preterm birth, which is similar 
to our two lesion groups(179). Low birth weight <2500 g had an OR above 1.0 in all 
our lesion groups, while mean birth weight was higher in CHD lesion group 2, 4 and 
6 compared with controls. This indicates a variation between individuals within the 
lesion groups, which might be addressed by going into detail of the diagnoses, by ad-
justing for maternal comorbidities and for socioeconomic factors. Perinatal death was 
similar to the Canadian study (0.8% vs 0.2%), however they considered their numbers 
to be underreported(168). 
The prevalence of cardiac malformations in the neonate was over four times as high in 
CHD women compared with controls in our study. We did not analyze if the cardiac 
malformation was the same as in the mother or if there were concomitant syndromes. 
Patients with autosomal dominant hereditary syndromes were not excluded. Oyen 
et al found a relative risk of recurrence of 3.4 to 79.1 depending on the  rst-degree 
relative´s cardiac defect, with an over-all relative risk of  8.15 (95% CI, 6.95-9.55) for 
the same heart defect phenotype(12). The lowest risk of recurrence in our study was in 
the ASD lesion group and the highest in the conotrunchal lesion group.
In conclusion, women with CHD have higher probability of cardiac, obstetric and 
neonatal complications during pregnancy compared to women without CHD. How-
ever, the absolute risk for the total cohort is low.  
55
Paper IV
NTproBNP during and after pregnancy in healthy women.
We studied a pre-pregnancy healthy cohort, to the best of our knowledge larger than 
reported before, with serial measurements of heart biomarkers during pregnancy, peri-
partum and at 6 months postpartum. Although cardiac output was higher in the second 
trimester compared with 6 months postpartum (5.6 vs 4.4 l/min, 27% change, unpub-
lished data), NTproBNP levels were the lowest at the second trimester measurement. 
Hemodilution and glomerular  ltration rate were the highest in the second trimester. 
We believe that this re ect the low NTproBNP levels seen in mid-pregnancy. The high-
est levels of NTproBNP during pregnancy were found in the  rst trimester with levels 
not signi cantly different from 6 months postpartum. The hemodynamic changes with 
hemodilution were reported in a systematic review to be increased by 8% in the  rst 
trimester and by 23% in the second trimester compared with non-pregnant reference 
levels(33). In our study, EVF was 3% lower in the  rst, and 13% lower in the second 
trimester compared to 6 months postpartum. We did not measure third trimester levels 
of NTproBNP why comparison with other studies including third trimester cannot be 
done, but  rst and second trimester levels are comparable with others(42, 76, 77).
The peripartum measurements 17-34 hours after delivery can be compared with two 
previous reports on measurements 2-6 days and <48 h after delivery(42, 77). Both found 
considerably higher levels of NTproBNP post-delivery with median 127 (5th-95th per-
centile 22-396) and median 107 (range 61-202) compared with our median 44 (range 
5-990) in the total cohort. One difference between the two studies and ours was the 
rate of cesarean section, which was 47% in the Umazume and 33% in the Burlingame 
study, while our CS rate was 15%. Cesarean section (not speci ed whether acute or 
planned) was found to result in higher NTproBNP levels day 3 postpartum compared 
with vaginal delivery in a study on 78 healthy women(216).  
A related biomarker, BNP, has been studied. No change in BNP levels between trimes-
ters were found but sample size was low and the reference group were non-pregnant 
controls. All had BNP levels below a cut-off level of 100 ng/l for heart failure(80, 83). 
When comparing BNP to NTproBNP the latter is more affected by renal function. 
In our unpublished data of the total cohort we found mean EVF 0.36 in vaginal and 
0.32 in CS deliveries. The volume shift patterns post-delivery may differ between 
vaginal and CS deliveries. NTproBNP levels in relation to EVF were stable, without 
signi cant changes during pregnancy, peripartum and 6 months postpartum, which in-
dicate that a presumably higher NTproBNP production with increased cardiac output 
during pregnancy is balanced with hemodilution and increased glomerular  ltration. 
Hopkins et al found a correlation between hypoxia (which cause high EVF) and el-
evated NTproBNP(68). On the other hand, in a cohort of blood donors NTproBNP was 
lower with higher hemoglobin after adjusting for sex and age. EVF was not reported 
but was probably not elevated since the subjects were healthy, however only 3% were 
women aged 18-39 years(53). One explanation might be that the NTproBNP levels 
were not adjusted for creatinine. Elevated creatinine, which would increase NTproB-
NP levels, is associated with low hemoglobin(217). BMI increased between  rst and 
56
second trimester, which could affect the levels of NTproBNP downwards. The weight 
change is caused by a combination of body  uid, fat and a growing fetus(218). The re-
lationship between NTproBNP and body composition has not been studied. In a study 
on BNP, high levels were associated with body weight changes during pregnancy and 
delivery(81).  
Preeclampsia is a condition with endothelial dysfunction, vasoconstriction and hemo-
concentration(84, 219). NT proBNP is elevated in preeclampsia in most series compared 
to reference groups, which is presumed to be related to afterload increase(220-222). In 
the study by Ra k et al there was no correlation with eGFR, while Seong et al found 
a strong correlation with creatinine and a negative correlation with hemoglobin(85). 
There are studies on natriuretic peptides in pregnant women with heart disease. In a 
small study on seven women with dilated cardiomyopathy during pregnancy four of 
them had NTproBNP levels above 300 ng/l(223). 
CHD studies have shown increased levels of NTproBNP in non-pregnant patients 
and in pregnant CHD patients BNP levels were higher than in healthy controls(65, 66, 82). 
NTproBNP above 128 ng/l in 20 gw was associated with cardiovascular events during 
pregnancy in a CHD cohort. That level was derived as 95th percentile of pre-pregnancy 
healthy women from midwife centers, but the number of healthy controls were not re-
ported. However, there was no comparison with pre-pregnancy levels and a majority 
of cardiovascular events affected patients with cardiac diagnoses where there might 
be elevated levels also in non-pregnant state, which makes interpretation dif cult(86). 
In our study there were  ve women with NTproBNP levels above 300 ng/l, none of 
which had cardiac complications. Levels above upper limit of normal of 125 ng/l 
were more common with 8-9% during pregnancy and 15% peripartum. Levels below 
125 ng/l peripartum was associated with higher eGFR as expected, administration of 
oxytocin as postpartum hemorrhage profylaxis exclusively and spontaneous vaginal 
delivery. The NTproBNP upper limit of normal (95th percentile) in our selected cohort 
without events was 155 ng/l at 10-12 gw, 139 ng/l at 20-25 gw, 155 ng/l within 17-34 
hours postpartum  and 151 ng/l at 6 months postpartum which can serve as reference 
levels in similar populations. The cut-off level of <300 ng/l for ruling out heart failure 
is based on studies in older populations, including men, with a diversity of risk factors 
and chronic diseases and is not representative for our study cohort(48). 
The sensitivity of NTproBNP for heart failure is high but the speci city is lower, 
resulting in patients with levels above 300 ng/l without heart failure(46). On the other 
hand, patients with heart failure rarely have levels below 300 ng/l. Six blood samples 
in  ve women had levels above 300 ng/l in our total of 629 taken blood samples. The 
speci city was 99%, but sensitivity could not be calculated. In 60 blood samples, 
the levels were >125 ng/l resulting in a speci city of 90%. The majority of elevated 
levels were at the peripartum measurement when there was no echocardiography per-
formed, but medical history and physical examination 6 months postpartum revealed 
no clinical signs of heart failure. We  nd it acceptable to use the cut-off level of 300 
ng/l knowing that it may result in extended blood samples and echocardiography in 
few cases. 
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Troponins during and after pregnancy in healthy women
There are few reports on Troponin I and cTNT during pregnancy and delivery(42, 78, 79). 
In our study 0.6-2% of the blood samples during pregnancy and 6 months postpar-
tum were above 5 ng/l, which is the cut-off used for normal levels at our lab. On the 
other hand, at the peripartum measurement (17-34 hours post-delivery) 55% had lev-
els above the cut-off, which was associated with time from delivery to blood sample. 
There was no signi cant association with eGFR or delivery mode. In a study on TNI 
(not hs-TNI) in 51 women during labor and 24 h postpartum, the maximum level was 
found 24 h post-delivery. In that study, 20% had oxytocin as labor augmentation and 
90% were vaginal deliveries. None had TNI levels above cut-off(79). Umazume et al 
also found signi cantly elevated hs-TNI levels post-delivery 2-6 days compared with 
 rst trimester levels. There was a signi cant difference between vaginal deliveries 
with higher hs-TNI levels compared with levels in CS(42). There was no information if 
all CS in the Umazume study were elective. 
We did not  nd a statistical difference between delivery mode and hs-cTNT above and 
below 5 ng/l. We included both elective and emergency CS as well as assisted vaginal 
deliveries in the “other” group as opposed to spontaneous vaginal delivery. Some of 
them were in active labor before CS, which could affect the levels. Physical activity 
can increase the levels of hs-cTNT and thereby make the difference between groups 
less pronounced(74). cTNT and cTNI was studied in a cohort of women with normal 
pregnancy or hypertensive pregnancy at 36 gw compared with non-pregnant women. 
There was no statistical difference in troponins between non-pregnant women and 
pregnant women, while preeclamptic women had higher levels(78). We had no samples 
from the third trimester but the Umazuma study found somewhat elevated levels of 
hs-TNI during the third trimester compared with the  rst (median 1.3 vs 0.8 ng/l). 
One month postpartum the median was 1.2 ng/l, still higher than  rst trimester, which 
indicate that pregnancy per se not is associated with elevated troponins. This is in ac-
cordance with our 6-month visit when 2% had levels above 5 ng/l. The relevance of 
elevated biomarkers 6 months postpartum has not been investigated, but our physical 
examination including echocardiography and symptoms reported by the participants 
revealed no overt pathology.  
Oxytocin is used both as labor augmentation and as postpartum hemorrhage prophy-
laxis. ST-depression on Holter-ECG within 3 minutes after administration of two dif-
ferent doses of oxytocin in CS as prophylaxis has been reported(224). The authors found 
an association with ST depression and chest symptoms with the higher bolus dose of 
10 units (16.7 μg) compared with 5 units (8.3 μg). TNI 24 h post-delivery were not 
statistically different between the groups. We found no statistically signi cant differ-
ence with the use of oxytocin and hs-cTNT above or below 5 ng/l. There was a non-
signi cant difference in hs-cTNT >5 ng/l (43% vs 25%) for women receiving labor 
augmentation oxytocin, which may be related to prolonged labor, i.e. physical effort.
Three women had hs-cTNT levels above 14 ng/l at the peripartum measurement 
which is set as cut-off below which myocardial infarction is unlikely. None of them 
had signs or symptoms by medical records of myocardial ischemia; however, ECG or 
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second trimester, which could affect the levels of NTproBNP downwards. The weight 
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Troponins during and after pregnancy in healthy women
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echocardiography were not performed at that measurement. All of them had fullterm 
spontaneous vaginal deliveries and none had renal insuf ciency (the lowest eGFR 
was 84 ml/min/1.73). One of them had fever but otherwise none had complications, 
hemoglobin within normal, one had epidural anaesthesia, there was one in each of 
the three oxytocin groups and birthweights were 3475-3700 g. The 95th percentile 
of hs-cTNT at the peripartum level was 12 ng/l and the speci city was 99.5% of all 
samples (3/628) and 97.5% at the peripartum measurement (3/119), why we mean that 
the existing cut-off of 14 ng/l is reasonable. In conclusion, existing cut-off levels of 
heart biomarkers NTproBNP and hs-cTNT can be applied to rule out cardiac cause in 
pregnant women with symptoms of dyspnea or chest pain. 
Clinical implications
With increasing number of pregnancies in women with both congenital heart dis-
ease and acquired heart disease, dedicated multidisciplinary collaboration and units 
have started. The GUCH/ACHD center in Gothenburg started multidisciplinary con-
ferences on pregnancy in women with congenital heart disease in 2008. The multi-
disciplinary collaboration preferably should include cardiac, anesthetic and obstetric 
competence with the possibility to engage other disciplines when needed.
Pre-pregnancy counseling, planning visits during pregnancy and delivery as well as 
contraception issues are important in women with congenital heart disease(40, 225-227). 
Using risk classi cations together with information on comorbidities and functional 
testing form the basis for counseling. Adding additional predictors to the mWHO clas-
si cation is recommended in the ESC guidelines(175). We did not  nd maternal age to 
be associated with cardiac complications. However, the risk for cardiac complications 
(and concomitant change in risk score classi cation) increase by age in CHD popula-
tion. Advanced maternal age is associated with obstetric and neonatal complications 
in the literature, even if we did not  nd signi cant associations. If the woman had a 
previous pregnancy, we can anticipate the same cardiac outcome if her risk classi ca-
tion still is the same.
Decreased heart rate response during exercise and pre-pregnancy cardiopulmonary 
exercise test with maximum oxygen uptake below 25 ml/kg/min has been associated 
with unfavorable maternal and neonatal outcome(228, 229). Exercise testing indicate if 
cardiac output can increase, as in pregnancy, without symptoms. Heart biomarkers 
may add to the assessment of pregnant women. There are few publications on bio-
markers in pregnant women with CHD(82). NTproBNP levels >128 ng/l at 20 weeks of 
gestation was associated with cardiovascular events(86). Knowing normal changes of 
heart biomarkers during pregnancy indicate which changes might be anticipated dur-
ing pregnancy in CHD women, especially if pre-pregnancy levels are known. 
In the care for CHD women issues on reproduction and pregnancy need to be ad-
dressed regularly. Imaging, testing of physical performance and identifying cardiac 
and obstetric risk factors should preferably be done before pregnancy and subse-
quently be re-evaluated. Since there are no perfect risk classi cations, the dedicated 
multidisciplinary team need to contribute with expertise and experience of cardiac, 
anesthetic and obstetric problems that might occur during pregnancy. Written plans 
59
for follow up during pregnancy and after delivery, plan for the delivery with individu-
alized cardiac, anesthetic and obstetric aspects are needed to assure the safest possible 
care for mother and child.
Strengths and limitations
Paper I. Strengths of the study is access to medical and obstetric records. Congeni-
tal heart diagnoses, previous cardiac complications, number of previous pregnancies 
and miscarriages are reliable data. Outcome of pregnancy and neonatal complications 
were also easily accessible. Categorizing in CARPREG I and mWHO-classi cation 
was done by one author, why all participants were classi ed in the same manner. 
Limitations are the proportion of women above 35 years (15%) when comparing age 
above and below. In obstetric literature 35 years is a frequently used cut-off when 
analyzing obstetric and neonatal outcome, but there is no agreed age suitable for com-
parison of cardiac outcome. Dichotomizing age might lead to undetected outcome 
within other age ranges. We analyzed composites of cardiac, obstetric and neonatal 
complications. One of the parameters within a composite might be statistically signi -
cant, however undetected among the composite group. We chose to not evaluate the 
ZAHARA classi cation, however it is the only classi cation based on CHD women 
exclusively. CARPREG II classi cation was not available at the time. 
Paper II. Strengths of the study were access to data from the same women in repeated 
pregnancies, with risk classi cations continuously updated between every pregnancy 
and very low missing data on cardiac outcome. Other authors have reported parity, but 
mostly in terms of primiparous  or multiparous participants. Patients with a previous 
successful pregnancy want to know the chances of a successful second pregnancy, 
which cannot be answered by that type of categorization. Another strength is two-year 
follow up after pregnancy, since the literature on prognosis after pregnancy is scarce.
Limitations were missing data on smoking habits and BMI why adjustment in the 
analysis was unsatisfactory. The aim was to study cardiac complications, why ob-
stetric and neonatal odds ratios were not reported. The number of participants with 
multiple pregnancies >2 was too small to evaluate the outcome of the third to eighth 
pregnancies separately, why they were analyzed as one group.
Paper III. Strengths are the population based design with large nationwide registries 
and personal identi cation numbers used when linking between registers which ascer-
tain that we obtained data on the correct individual. National data during many years 
generate a large number of participants and controls that make comparison between 
CHD and non-CHD reliable. There is no selection of participants depending on ac-
cess to care, since public  nanced health care is available to all Swedish citizens. The 
validity of cardiac diagnoses in NPR and obstetric data in MBR is acceptable(203, 230-232). 
Personal linked data entail the possibility to  nd the  rst time an ICD-code was regis-
tered and analyze if a condition was present before, during or after pregnancy. 
Limitations are changes during the studied time period in cardiac and obstetric care, 
health status in the population, ICD-code systems and validity of parameters which 
58
echocardiography were not performed at that measurement. All of them had fullterm 
spontaneous vaginal deliveries and none had renal insuf ciency (the lowest eGFR 
was 84 ml/min/1.73). One of them had fever but otherwise none had complications, 
hemoglobin within normal, one had epidural anaesthesia, there was one in each of 
the three oxytocin groups and birthweights were 3475-3700 g. The 95th percentile 
of hs-cTNT at the peripartum level was 12 ng/l and the speci city was 99.5% of all 
samples (3/628) and 97.5% at the peripartum measurement (3/119), why we mean that 
the existing cut-off of 14 ng/l is reasonable. In conclusion, existing cut-off levels of 
heart biomarkers NTproBNP and hs-cTNT can be applied to rule out cardiac cause in 
pregnant women with symptoms of dyspnea or chest pain. 
Clinical implications
With increasing number of pregnancies in women with both congenital heart dis-
ease and acquired heart disease, dedicated multidisciplinary collaboration and units 
have started. The GUCH/ACHD center in Gothenburg started multidisciplinary con-
ferences on pregnancy in women with congenital heart disease in 2008. The multi-
disciplinary collaboration preferably should include cardiac, anesthetic and obstetric 
competence with the possibility to engage other disciplines when needed.
Pre-pregnancy counseling, planning visits during pregnancy and delivery as well as 
contraception issues are important in women with congenital heart disease(40, 225-227). 
Using risk classi cations together with information on comorbidities and functional 
testing form the basis for counseling. Adding additional predictors to the mWHO clas-
si cation is recommended in the ESC guidelines(175). We did not  nd maternal age to 
be associated with cardiac complications. However, the risk for cardiac complications 
(and concomitant change in risk score classi cation) increase by age in CHD popula-
tion. Advanced maternal age is associated with obstetric and neonatal complications 
in the literature, even if we did not  nd signi cant associations. If the woman had a 
previous pregnancy, we can anticipate the same cardiac outcome if her risk classi ca-
tion still is the same.
Decreased heart rate response during exercise and pre-pregnancy cardiopulmonary 
exercise test with maximum oxygen uptake below 25 ml/kg/min has been associated 
with unfavorable maternal and neonatal outcome(228, 229). Exercise testing indicate if 
cardiac output can increase, as in pregnancy, without symptoms. Heart biomarkers 
may add to the assessment of pregnant women. There are few publications on bio-
markers in pregnant women with CHD(82). NTproBNP levels >128 ng/l at 20 weeks of 
gestation was associated with cardiovascular events(86). Knowing normal changes of 
heart biomarkers during pregnancy indicate which changes might be anticipated dur-
ing pregnancy in CHD women, especially if pre-pregnancy levels are known. 
In the care for CHD women issues on reproduction and pregnancy need to be ad-
dressed regularly. Imaging, testing of physical performance and identifying cardiac 
and obstetric risk factors should preferably be done before pregnancy and subse-
quently be re-evaluated. Since there are no perfect risk classi cations, the dedicated 
multidisciplinary team need to contribute with expertise and experience of cardiac, 
anesthetic and obstetric problems that might occur during pregnancy. Written plans 
59
for follow up during pregnancy and after delivery, plan for the delivery with individu-
alized cardiac, anesthetic and obstetric aspects are needed to assure the safest possible 
care for mother and child.
Strengths and limitations
Paper I. Strengths of the study is access to medical and obstetric records. Congeni-
tal heart diagnoses, previous cardiac complications, number of previous pregnancies 
and miscarriages are reliable data. Outcome of pregnancy and neonatal complications 
were also easily accessible. Categorizing in CARPREG I and mWHO-classi cation 
was done by one author, why all participants were classi ed in the same manner. 
Limitations are the proportion of women above 35 years (15%) when comparing age 
above and below. In obstetric literature 35 years is a frequently used cut-off when 
analyzing obstetric and neonatal outcome, but there is no agreed age suitable for com-
parison of cardiac outcome. Dichotomizing age might lead to undetected outcome 
within other age ranges. We analyzed composites of cardiac, obstetric and neonatal 
complications. One of the parameters within a composite might be statistically signi -
cant, however undetected among the composite group. We chose to not evaluate the 
ZAHARA classi cation, however it is the only classi cation based on CHD women 
exclusively. CARPREG II classi cation was not available at the time. 
Paper II. Strengths of the study were access to data from the same women in repeated 
pregnancies, with risk classi cations continuously updated between every pregnancy 
and very low missing data on cardiac outcome. Other authors have reported parity, but 
mostly in terms of primiparous  or multiparous participants. Patients with a previous 
successful pregnancy want to know the chances of a successful second pregnancy, 
which cannot be answered by that type of categorization. Another strength is two-year 
follow up after pregnancy, since the literature on prognosis after pregnancy is scarce.
Limitations were missing data on smoking habits and BMI why adjustment in the 
analysis was unsatisfactory. The aim was to study cardiac complications, why ob-
stetric and neonatal odds ratios were not reported. The number of participants with 
multiple pregnancies >2 was too small to evaluate the outcome of the third to eighth 
pregnancies separately, why they were analyzed as one group.
Paper III. Strengths are the population based design with large nationwide registries 
and personal identi cation numbers used when linking between registers which ascer-
tain that we obtained data on the correct individual. National data during many years 
generate a large number of participants and controls that make comparison between 
CHD and non-CHD reliable. There is no selection of participants depending on ac-
cess to care, since public  nanced health care is available to all Swedish citizens. The 
validity of cardiac diagnoses in NPR and obstetric data in MBR is acceptable(203, 230-232). 
Personal linked data entail the possibility to  nd the  rst time an ICD-code was regis-
tered and analyze if a condition was present before, during or after pregnancy. 
Limitations are changes during the studied time period in cardiac and obstetric care, 
health status in the population, ICD-code systems and validity of parameters which 
60
may have changed during the time studied. The gestational week for inclusion in the 
MBR changed 2008 from 28th gestational week to 22nd, why stillbirth and maternal 
death in early pregnancy might be underreported in the earlier time period. However, 
data on all live birth pregnancies are reliable and both CHD and non CHD are reported 
in the same way. Diagnoses in outpatient care were not reported until 2001 why cardi-
ac and obstetric events handled without hospitalization might be underreported before 
that. ICD-codes do not contain information on the severity of the diagnosis, which is 
better studied in single- or multicenter studies or in disease-speci c registries. Catego-
rizing in lesion groups inevitably lead to conclusions on the whole lesion group while 
information on subgroups might be lost. A diagnosis with high event rate might be 
evened up with a low event rate diagnosis within the lesion group. 
We analyzed all cause maternal death during pregnancy and one year postpartum 
using the date of death from the Cause-of-death register, but have not analyzed the 
actual cause. We did not analyze if there were differences in emigration during follow 
up between CHD and controls, but we have no belief that the cohorts would differ (ap-
proximately 0.4% of women emigrate per year). We did not adjust for socioeconomic 
variables, which is possible to do by linking to other registers. There may be other 
unmeasured and unknown confounding factor not taken into account. The cohort was 
primiparous women with singleton pregnancies, why outcome is not representative 
for multiple pregnancies or multiparous women.
Paper IV. Strengths of the study are among others that the women were their own 
controls since, for example, BMI and renal function affect levels of biomarkers. 
This is the  rst study to analyze hs-cTNT and the largest in analyzing NTproBNP in 
pregnancy. Another strength is the physical examination including echocardiography 
to verify that the participants were healthy. We reported a cohort of pre-pregnancy 
healthy women, but also a subgroup of normal-weight women without any obstetric 
events. There are different heart biomarkers in use in different parts of the world and 
we choose to analyze the ones in use at our hospital. The participants were recruited 
from different socioeconomic areas at the antenatal clinics. 
Limitations of the study are  possible bias towards recruiting women with an interest 
in health issues having the time to come to appointments, women with worries about 
the pregnancy or women with familial cardiac problems. We do not have access to the 
number of participants who denied participation. The majority were of Caucasian eth-
nicity why our results should be interpreted with caution in other parts of the world. 
Main fi ndings
Women with CHD had higher probability of cardiac, obstetric and neonatal complica-
tions during pregnancy than non-CHD women. The absolute risks reported in regis-
tries were low, but compared with controls all three adverse outcomes were elevated. 
The CHD-diagnosis pattern, as well as health status parameters, changed from 1973 
to 2015. 
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Our single center cohort of CHD women had higher risk of complications during 
pregnancy than what was found in nationwide registries. However, this Swedish 
single-center data on risks were comparable with international literature.
Maternal age above 35 years was not associated with adverse outcome during preg-
nancy. There is a known increase in cardiac complications by age in all CHD patients, 
but pregnancy was tolerated well also in women above 35 years. 
Two risk classi cations (CARPREG I and mWHO) were acceptable, but not good, in 
predicting complications during pregnancy in our single center cohort. 
There was a high probability that the second pregnancy had the same maternal cardiac 
outcome as the  rst pregnancy in women with CHD. However, change in risk classi-
 cation group between the pregnancies affect the probability. There were few cardiac 
interventions during two-year follow-up after pregnancy.
The biomarkers NTproBNP and hs-cTNT levels during pregnancy and peripartum in 
pre-pregnancy healthy women were below the levels when heart failure or myocardial 
infarction should be suspected. 
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FUTURE PERSPECTIVES
Further national register studies could evaluate the short- and long-term effects on 
pregnancy-related complications in women with CHD. CHD as a group is diversi ed 
and some diagnoses might be more susceptible for future morbidity than others. The 
registers contain data on rare diagnoses that are dif cult to  nd in adequate numbers 
to evaluate in single- or even multicenter studies. We found the majority of pregnan-
cies in women with CHD to be without severe complications, but when complications 
occur, it may affect both mother and offspring. Thus, it is important to further evaluate 
separate, rare CHD diagnoses. With national register data, there is low risk of selection 
bias. Validation of CHD diagnoses and outcome data is valuable for future research.
Comparing regime of operations between men and women with the same CHD di-
agnosis and operation technique would also be possible from nationwide registers. 
Choice of valve substitute, timing of interventions for example and thereby prognosis 
could differ between the sexes.Prediction of complications are philosophically dif -
cult, since we are biased from start and chose factors that we think are important, and 
then analyze them. Using arti cial intelligence to  nd possible predictors is tempting, 
especially since we have access to big data and the research team are familiar with the 
methods. We might  nd previously unknown predictors to add to current knowledge.
However, national registers held by The Swedish National Board of Health and Wel-
fare cannot give detailed cardiac information on severity of valve stenosis, degree of 
cyanosis or ventricular dysfunction, while obstetric data are easier to obtain. Linking 
to the SWEDCON register could give contribution with more detailed information on 
the CHD characteristics and severity of diasese. The ROPAC register, collect and re-
port detailed information on pregnancy in women with congenital and acquired heart 
diseases and is ongoing. Since several years, there is a Nordic collaboration between 
CHD-centers. The countries have similar health care systems and registers, why col-
laboration is reasonable to get solid data and large numbers. So far, none of the Nordic 
projects has addressed pregnancy.
Pre-pregnancy evaluation using cardiopulmonary exercise tests in combination with 
biomarkers and early postpartum assessment after vaginal and CS deliveries would be 
useful to con rm (or reject) the few previous studies on these themes. The relationship 
between cardiac performance and utero-placental blood  ow has been studied and 
would be interesting to further describe. Cyanotic conditions, Fontan circulation and 
women with aortopathies would be of special interest to further understanding of he-
modynamics in CHD pregnancy. There are no qualitative studies on how CHD wom-
en experience pregnancy-related symptoms; how to separate normal pregnancy symp-
toms from worsening of the heart condition. Guidelines recommend pre-pregnancy 
counseling because as physicians, we think it is our duty to inform about possible con-
sequences but there is little knowledge on how the information is perceived(233). We 
have had multidisciplinary conferences with a written plan for delivery in Gothenburg 
since more than a decade. Still, there is no evaluation of adherence and effectiveness 
of the conference and no comparison with other CHD centers.
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PERSONAL REFLECTIONS
During almost twenty years of work with CHD-patients. I am 
used to get questions that have no obvious answers. The search 
for knowledge, to get ideas, make hypotheses, discuss with col-
leagues and draw conclusions is even more satisfying when the 
result can be translated into clinical practice. I am privileged to 
have the opportunity to search for answers to some of the ques-
tions I got during the years from young women in the beginning 
of a long journey. It is as important to give reassuring advice to 
low-risk patients as to identify high-risk patients, plan for the best 
outcome and be prepared to advise against pregnancy. In pre-
pregnancy counselling there is a need of profound knowledge of 
the individual´s diagnosis and hemodynamic situation as well as 
obstetric considerations, why multidisciplinary collaboration is 
essential. I am fortunate to work in that kind of environment.
The unanswered questions have the same potential as a seed; it may fall into soil with 
the appropriate mix of nutrients (research team, university, funding), start to grow and 
prosper (colleagues and supervisors) and  nally give fruit (results and answers). 
Within that fruit there are numerous of new seeds….
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FUTURE PERSPECTIVES
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